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Breast cancer remains the leading malignancy among women in the United 
States, affecting an estimated 246,660 women in 2016. Breast cancer can be separated 
into three groups known as estrogen receptor/ progesterone receptor positive 
(ER+/PR+), Her2/neu positive (HER2+), and triple negative (ER-/PR-/HER2-) subtypes. 
The majority of breast cancers rely on estrogen to stimulate their growth and survival. 
Estrogen is produced from precursor hormones by the aromatase enzyme, whose 
action can be blocked with aromatase inhibitors (AIs). Unfortunately ~40% of breast 
cancer patients are resistant to this treatment and their breast tumors either continue to 
grow or recur despite depletion of circulating estrogen. The precise cause of AI-
resistance is not known. Our lab aims to determine the mechanisms that allow breast 
cancer cells to survive in estrogen-depleted conditions. We have previously reported the 
generation of an AI-resistant breast cancer cell line, MCF-7:5C, which was isolated 
under estrogen-free conditions from the estrogen-dependent breast cancer cell line 
MCF-7. The MCF-7:5C cell line is highly aggressive and overexpresses several 
interferon stimulated genes including, interferon inducible transmembrane protein 1 
(IFITM1).   
IFITM1 is a type 1 interferon (IFN) stimulated gene (ISG) that is not expressed in 
normal breast tissue, and is only induced by the type1 IFNs (IFNα and β) to protect the 
host from viral infections. IFNα signals through a specific receptor, IFNAR, which uses 
JAK/STAT signaling to produce the ISGs. ISGs are known to drive the progression of 
other cancer types, to inhibit apoptosis and promote DNA damage resistance. However, 
the significance of constitutive overexpression of ISGs in AI-resistant breast cancer is 
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not known. We hypothesize that IFITM1 overexpression contributes the AI-resistant 
phenotype and promotes breast cancer cell aggression and survival.  
In this thesis, we demonstrate that IFITM1 is overexpressed in breast tumors and 
is correlated with poor response to endocrine therapy using in silico analysis of breast 
tumor expression databases and a human tissue microarray. Gain and loss of function 
studies in an IFITM1-overexpressing AI-resistant breast cancer cell line, MCF-7:5C, and 
an IFITM1-null AI-sensitive breast cancer cell line, MCF-7, reveal that IFITM1 promotes 
the AI-resistant aggressive phenotype and estrogen-independent growth. Additionally, 
the orthotopic (mammary fat pad) and mouse mammary intraductal (MIND) models of 
breast cancer evaluate the role of IFITM1 in tumor growth and invasion respectively. We 
report that loss of IFITM1 induced cell death in AI-resistant MCF-7:5C cells results in 
marked increases in p21/Waf1/Cip1 transcription, expression and nuclear localization. 
Notably, p21 transcriptional upregulation was mediated by STAT1 activation. These 
findings suggest IFITM1 overexpression contributes directly to breast cancer 
progression and that it may be a therapeutically relevant target in the treatment of 
endocrine-resistant breast cancer. 
Mechanistic studies reveal that MCF-7:5C cells produce elevated levels of IFNα 
as compared to MCF-7 cells and that this cytokine binds to the type 1 IFNα receptor, 
IFNAR, and induces JAK/STAT signaling, ultimately resulting in the overexpression of 
IFITM1. Independently, we also find that mucin 1 (MUC1) associates with STAT1 and 
stabilizes its phosphorylated form, thereby contributing directly to IFITM1 expression. 
MUC1 expression is hormonally controlled and is normally enhanced by estrogen 
stimulation. We find that MUC1 expression is dysregulated in AI-resistant MCF-7:5C 
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cells and is instead reduced by estrogen stimulation. MCF-7:5C cells are sensitive to 
apoptosis following exposure to estrogen, which can be enhanced by loss of IFITM1 
expression. Loss of MUC1 expression similarly enhances estrogen-induced apoptosis, 
suggesting that the communication between MUC1 and STAT1 also influences 
estrogen signaling in AI-resistant breast cancer. In this thesis, we conduct investigations 
into the mechanisms and functional significance of IFITM1 expression in AI-resistant 
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CHAPTER 1 : BACKGROUND AND INTRODUCTION 
BREAST CANCER STATISTICS AND RISK FACTORS 
Breast cancer remains the most prevalent malignancy among women, 
accounting for about 30% of all cancer cases diagnosed in the United States, and a 
total of 246,660 new cases in 2016.10,11  While the incidence of breast cancer has 
decreased continuously in recent decades, it is still estimated that 1 in 8 women will 
develop breast cancer in her lifetime.12,13 Additionally, several risk factors for the 
development of a breast malignancy have been identified. It is known that having a 
personal or family history of breast cancer, as well as certain genetic mutations, such 
those in the BRCA1/2 DNA repair genes increases breast cancer risk. The remaining 
well-known risk factors: female gender, age, use of hormone replacement therapy or 
oral contraceptives, early menarche, late menopause, obesity and alcohol intake all 
increase the chance of developing breast cancer because they increase a woman’s 
lifetime exposure to estrogen.14,15  
ESTROGEN AND ESTROGEN SIGNALING IN BREAST CANCER 
Estrogen is a steroid hormone that is essential for normal development of the 
female reproductive organs, as well as the bones and heart.16 Estrogen promotes the 
growth and differentiation of target tissues by binding to the estrogen receptor (ER). 
Traditionally, ER functions as a classic steroid hormone receptor. Ligand activated ER 
enters the nucleus and dimerizes allowing for transcription factor function. 17 Active ER 
then binds to estrogen responsive elements (ERE) in the promoters of hundreds of 
genes, most of which promote cell cycle progression and growth.16 ER can also be 
palmitoylated, which localizes it to the cell membrane. There ER interacts with the 
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adaptor proteins Shc and calveolin-1.18 These interactions allow ER to signal through 
rapid phosphorylation cascades, using many cell signaling mediators, including G-
protein coupled receptors, Src tyrosine kinases and PI3K.17,18 The latter interaction also 
mediates cell growth and survival by facilitating Akt activation, which promotes the 
expression of cell cycle and pro-survival genes as well. Rapid signaling through 
membrane bound ER is also known to recruit β-tubulin, which increases promotes cell 
migration.18 Due to the many beneficial effects of ER signaling, most breast cancers 
utilize estrogen to facilitate their growth, survival and invasion (Figure 1.1).  
In postmenopausal women, the ovaries and adrenal glands produce the hormones testosterone and 
androstenedione. Estrogen is synthesized in peripheral tissues such as adipose tissue, breasts and 
skin through the action of aromatase, which converts androstenedione and testosterone to estrone 
and estradiol. Estrogen receptor-positive (ER+) breast cancer cells can also express aromatase, 
leading to intratumoral estrogen production. CoA, co-activator; ERE, estrogen response element.5 
Figure 1.1 Estrogen production and signaling in postmenopausal women. 




Roughly 75% of breast cancers are estrogen receptor positive (ER+) and the 
number of ER+ tumors is expected to continue to rise over the next decade.10,11,13 
Therefore, it is not surprising that women with higher circulating levels of estrogen have 
a higher risk of developing breast cancer. 16 This is not only because ER signaling 
promotes cell growth and proliferation, but also because estrogen metabolites are 
powerful carcinogens. Estrogen metabolites form DNA adducts, cleave purine bases, 
and generate free radicals, all of which induce DNA damage and promote epithelial 
transformation.19-21 Due to the many cancer promoting actions of estrogen, the 
predominate treatment for ER+ breast tumors is blockade of ER signaling. The main 
Estradiol binds to the estrogen receptor (ER), leading to dimerization, conformational change and 
binding to estrogen response elements (EREs) upstream of estrogen-responsive genes including 
those responsible for proliferation. Tamoxifen competes with estradiol for ER binding whereas 
aromatase inhibitors reduce the synthesis of estrogens from their androgenic precursors. Fulvestrant 
in turn binds to and induces degradation of ER. CoA, coactivator. 8 
Adapted from: Johnston & Dow sett. Nature Reviews Cancer 3, 821-831 (2003). 
 
Figure 1.2 Mechanisms of action of endocrine therapy 
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therapies for ER+ breast cancer target the estrogen receptor, estrogen production or 
estrogen signaling (i.e. endocrine therapy). This is accomplished by depletion of 
circulating estrogen with aromatase enzyme inhibition (AI), by blockade of ER signaling 
with selective estrogen receptor modulators (SERMs) such as tamoxifen, and by 
degradation of ER itself, with selective estrogen receptor down-regulators (SERDs) 
such as fulvestrant (Figure 1.2). All of these therapies have had profound anti-tumor 
benefits in the clinic.22,23 The introduction of endocrine therapy has resulted in 
significant reductions in ER+ breast cancer-related mortality. 
AROMATASE INHIBITOR RESISTANCE IN ER+ BREAST CANCER 
The AIs prevent estrogen production from precursor hormones by targeting the 
aromatase enzyme. These include non-steroidal anastrozole and letrozole as well as 
steroidal exemestane (Figure 1.2).11,24  All three compounds deplete circulating 
estrogen, effectively starving the breast cancer cells and stimulating cell cycle arrest 
and cell death, which results in tumor shrinkage and prevention of metastasis.25,26 Due 
to the unsurpassed effect on tumor progression, AI therapy is now the standard of care 
for women with ER+ breast cancer. Unfortunately, approximately 30% of women 
receiving AI treatment eventually develop resistance and the tumors continue to grow 
and metastasize despite the absence of estrogen.25-28 These AI-resistant tumors are 
typically more aggressive and are less responsive to other types of endocrine therapy, 
leaving radiation and chemotherapy as the main treatments available to these 
patients.28 The mechanism by which AI resistance develops in breast cancer and the 
molecular factors driving its aggressive phenotype are still not completely known.5  
While it is not known what drives AI-resistance, alterations in ER, growth factor, 
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PI3K/Akt/mTOR, apoptosis and autophagy signaling have been identified as potential 
mechanisms in both preclinical and clinical studies (Figure 1.3).27,29-31  
THE PARADOXICAL EFFECTS OF ESTROGEN 
Remarkably, in addition to the growth stimulating effects of estrogen, estrogen 
and estrogenic compounds can also have a pro-apoptotic role in breast cancer cells, 
known as the “estrogen paradox.”32 It should be noted that synthetic estrogens and 
estradiol were used for the treatment of advanced breast cancer starting in the 1940s 
until the advent of tamoxifen therapy in the 1970s.33,34  In fact, synthetic estrogens and 
tamoxifen exhibited similar tumor regression rates to tamoxifen in clinical trials and were 
only replaced as standard of care for breast cancer treatment because of a better side-
Figure 1.3 Mechanisms of AI-resistance. 
Several cell-autonomous and non-cell-autonomous mechanisms in estrogen receptor-positive (ER+) 
breast cancer and the tumor microenvironment could lead to aromatase inhibitor (AI) resistance. These 
include alterations in estrogen receptor (ER), such as mutations in/or loss of ER expression. Enhanced 
growth factor signaling can compensate for the loss of estrogen stimulation and changes in apoptosis 
or cell cycle proteins can promote cell survival and proliferation. IGF1R, insulin-like growth factor; 
EGFR, epidermal growth factor receptor; TP53, tumor protein 53; BCL-2, B cell lymphoma 2; Rb, 
retinoblastoma protein; CCND1, cyclin D1 5 




effect profile.35,36 As the number of patients developing resistance to endocrine therapy 
grew, the use of estrogens was investigated again in patients that had failed several 
rounds of hormone therapy.23,37-39 In these studies, a significant group of patients 
experienced marked decreases in tumor size, burden and mortality when treated with 
estrogens as compared to standard endocrine therapy. This concept, known as the 
“estrogen gap hypothesis” addresses the fact that high dose estrogen therapy is 
significantly effective in breast tumors that have been deprived of estrogen for at least 5 
years and also explains why older post-menopausal women have a lower incidence of 
breast cancer when placed on estradiol replacement therapy late in life.40,41  
Development of the long-term estrogen deprived (LTED) cell lines from ER+ 
MCF-7 and T47-D cells has allowed for investigation into the mechanism of estrogen-
induced tumor regression.42-44 Studies by our laboratory and others have revealed that 
estrogen induces stress response, intrinsic caspase-mediated and Fas death receptor 
mediated apoptosis in LTED cells.45-48 Estrogen-induced apoptosis is an ER-mediated 
phenomenon that likely results after adaptive hypersensitivity to estrogen in LTED cells. 
This hypersensitivity is thought to be due to upregulated growth-factor signaling in the 
estrogen-deprived state.49 In response to estrogen treatment, LTED cells receive growth 
and death signals simultaneously. The growth signals are thought to be mediated by 
insulin-like growth factor (IGF) signaling,  while the pro-apoptotic signals seem to begin 
with Akt degradation in the endoplasmic reticulum.50 Competing signals on the PI3K 
pathway likely maintains homeostasis in normal tissues but becomes out of balance in 
the LTED state.47 While investigation into the exact mechanism of estrogen-induced 
apoptosis continues, our laboratory has begun compiling a genetic profile that defines 
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tumors that are sensitive to estrogen therapy. One pathway that is overactive in LTED is 
the interferon (IFN) signaling pathway.46 
THE IFN FAMILY 
The IFN family consists of several cytokines that are known to have both pro- 
and anti-tumor functions.2 These proteins are produced by all nucleated cells in the 
body, including the cells of the immune system and epithelial cells at the site of 
inflammation or pathogen specific immune response.2,51 They all have antiviral activity, 
inhibit cell growth and control cell fate.51,52 The IFNs are transcribed by interferon 
Figure 1.4 Types of IFN Signaling.  
The IFNs bind to specific receptors which are heterodimers. The JAK family of kinases phosphorylates 
STAT proteins, which form a variety of transcription factor complexes. The STATs can homodimerize, 
heterodimerize and interact with other proteins which gives diversity to this signaling pathway. The 
activated complexes then enter the nucleus where they recognize specific promoter elements and 





response factors (IRFs) and actively secreted into the extracellular space where they 
signal in an autocrine and paracrine fashion, serving as a warning to adjacent epithelial 
and immune cells.51-53 The type I IFN family includes IFNα, IFNβ and IFNω. These cell-
to-cell messengers have been best characterized by their function in the immune 
system where they aid in defending host tissues from viral infection.2,53,54 The type I 
IFNs can be produced by any nucleated cell in the body when the presence of viral DNA 
or RNA is detected.  
The type II IFN family consists of only IFNγ, which facilitates the inflammatory 
response of the adaptive immune system. IFNγ is predominantly produced by T-cells 
when they are stimulated by specific antigens.2 This cytokine then activates other 
members of the adaptive immune system and modulates the immunogenicity of 
epithelial cells. The type III IFN family, which includes IFNλ1 and IFNλ2/3 (aka IL-29 
and IL-28A/B), also exhibits potent antiviral activity, but their impact on epithelial cells is 
still being characterized.3,55,56 Both IFNα and IFNγ have been used successfully as 
therapy for both blood and solid cancers because of their potent inhibition of cell 
proliferation, stimulation of MHCI expression and induction of pro-apoptotic genes.2,57 
IFN SIGNALING AND IFN STIMULATED GENES 
The IFNs all bind to specific integral cell membrane receptors that facilitate 
intracellular signaling through a variety of pathways, including phosphorylation 
cascades and Janus kinase (JAK)/signal transducer and activator of transcription 
(STAT) signaling (Figure 1.4).   The type I IFNs all bind to the type I IFN receptor 
(IFNAR) on the cell surface. IFNα and β utilize the JAK/STAT system, while IFN ω relies 
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on the phosphorylation cascade of the MAPK pathway.2 IFNγ binds a specific receptor, 
IFNγR, which uses JAK/STAT signaling in addition to the NFκB pathway and the 
PI3K/Akt and MAPK phosphorylation cascades for signaling.2 The Type III IFN receptor 
is a heterodimer comprised of one chain that it shares with the IL-10 receptor (IL-10R2) 
and also the IFN specific IL-28R1 chain. The type III IFNs rely predominantly on the 
JAK/STAT signaling pathway to mediate their antiviral functions.3 The IFNs and their 
receptors all have JAK/STAT signaling in common but different STAT proteins are 
preferred by different members of the IFN family. 
The signal transducer and activator of transcription (STAT) superfamily of 
proteins are latent transcription factors that are activated by the Janus kinase (JAK) 
family of phosphorylation proteins. Currently six STAT proteins have been identified and 
all enter the nucleus upon phosphorylation where they bind to specific elements in the 
promoters of their target genes. The STAT proteins can form homo- and heterodimers 
and also interact with other proteins to form a variety of transcription factor complexes, 
including the interferon response factor family (IRFs).6 This variety provides differing 
specificity for certain promoter elements. For example, the type I and type III IFNs both 
stimulate the formation of the IFN-stimulated gene factor 3 (ISGF3) complex, which is 
comprised of STAT1, STAT2 and IRF9.3,56  This results in the production of a similar 
array of interferon stimulated genes in both immune cells and epithelial cells. ISGF3 
binds to interferon stimulated response elements (ISREs) in the promoters of ISGs.58 
IFNγ, however, stimulates the formation of STAT1 homodimers which recognize gamma 
associated sequences (GASs). Traditionally, the STATs must be phosphorylated  in 
order to enter the nucleus and facilitate transcription but recent studies have found that 
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activity of the unphosphorylated STATs are capable of transcribing the ISGs.6 This 
phenomenon is thought to contribute to radiation, chemotherapeutic and hormonal 
resistance in cancer.54,59 
IFN stimulated genes (ISGs) mediate the effects of IFN signaling. There are 
thousands of ISGs and their specific roles in the antiviral response and modulation of 
cell fate are still being elucidated. Thus far the ISGs are known to prevent the fusion of 
viruses with the cell membrane, inhibit the translation of viral DNA, recognize viral RNA, 
bind and inhibit viral proteins, modulate the expression of cell cycle proteins and control 
the availability and activation of pro-apoptotic mitochondrial proteins.60-63 Expression of 
these ISGs is critical for preventing and controlling infection by a wide variety of DNA 
and RNA viruses and also determining cell fate.56,62,64-66 STAT1 and STAT2 themselves 
are considered ISGs and are overexpressed in breast cancer.67-69 Interestingly, STAT1 
knock out mice develop spontaneous ER positive mammary tumors, which highlights 
the critical role for STAT signaling in mammary development and the dual role that 
IFN/JAK/STAT signaling can play in cancer.70,71 Through the actions of the ISGs, IFN 
signaling can promote the controlled death of an infected cell and at the same time the 
survival of adjacent cells in an epithelial cell layer. It is the duality of IFN signaling that 
allows the same system to mediate IFN anti-cancer therapy and simultaneously 
augment tumor progression.6,54,59,72,73 
IFN STIMULATED GENES IN SOLID TUMORS 
Due to their modulation of cell fate, the ISGs have the potential to impact the 
development and progression of tumors. Acute high doses of IFNs tend to be cytotoxic, 
and so are used as anti-tumor therapy 72,74, but chronic exposure to low amounts of IFN 
11 
 
Table 1.1 Interferon Stimulated Genes (ISGs) 
associated with cancer progression and 
resistance to chemotherapy, radiation and 
hormonal therapy.6 
 
Adapted from: Chen et al. PNAS. 2009 Jun 9;106(23):9373-8 
 
stimulates the production of a unique subset of ISGs, which includes the Interferon 
Related DNA Damage Resistance Signature (IRDS), and these ISGs have been linked 
to cancer progression as well as 
chemotherapy, radiation and 
hormonal resistance (Table 
1.1).6,59,75,76 Additionally, expression 
of several ISGs (i.e. PLSCR1, 
IFITM1 and IFITM3) by various 
epithelial cancers promotes 
aggressive growth, invasion and 
tumor progression in both in vitro and in vivo models of colon, ovarian and breast 
cancer and in some clinical studies.59,73,75,77-79 The mechanism(s) by which ISGs 
facilitate tumor progression has not been elucidated.  
While the exact role that ISGs play in breast cancer is not yet known, there is 
strong evidence that aberrations of IFN signaling do have an impact on breast 
tumorigenesis and progression. Enhanced JAK/STAT signaling is pro-survival, pro-
proliferative and has been shown to confer resistance to chemotherapy and radiation in 
breast cancer specifically.54,75,80 The suppressors of cytokine signaling (SOCS) family 
specifically inhibits the phosphorylation capabilities of the JAK family, thus shutting 
down canonical JAK/STAT signaling. Silencing and down-regulation of SOCS proteins 
has been seen in both breast and ovarian cancer, and re-expression of SOCS1 can 
reduce cell growth.81,82  Conversely, higher expression of several SOCS family 
members confers a better prognosis for patients with breast cancer.81,83,84 Additionally, 
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interferon response factor 1 (IRF1), which also modulates ISG expression, exhibits 
some control over breast cancer cell death and is required for the apoptotic actions of 
anti-estrogen therapy.85-87 In addition to DNA-damage resistance, STAT1 and type 1 
IFN signaling  specifically have been linked to endocrine-resistance in breast cancer by 
several groups 59,68,73,88 and may actually define a separate molecular subtype of breast 
cancer termed “luminal-like.” 89 The luminal-like subset has been characterized by high 
ISG expression, including IFITM1, IFIT1, ISG15, IFI27 and MX1, and downregulation of 
ERBB2 and lipid signaling. This results in poorer prognosis than luminal breast tumors 
but better prognosis than the basal-like subtype.89 
The source of IFNs in the breast tumor microenvironment is still under 
investigation, but studies suggest that MAMs, dendritic cells, T-cells and the breast 
tumor cells themselves all are potential sources.59,72,73,90 IFN production by the 
mammary epithelial cells could be induced through stress, viral infection, persistent 
DNA damage, loss of p53 function or acquired genetic alterations (Figure 1.5).72,91 In 
breast cancer, the presence of stromal cells also seems to be crucial to ISG expression 
by the neoplastic epithelial cells. Stromal cell-induced ISG expression is dependent on 
STAT1 expression in the breast cancer cells and has been shown to induce radiation 
resistance in a mouse model.92 Modification of IFN signaling influences the drug 
sensitivity and prognosis of breast cancer but the specific role of individual ISGs 
remains to be elucidated. 
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INTERFERON INDUCED TRANSMEMBRANE PROTEIN 1 (IFITM1) 
Interferon-induced transmembrane protein 1 (IFITM1) is a member of the IFN-
inducible transmembrane protein family whose expression is strongly induced by type 1 
IFNs. 93 It was initially identified as a leukocyte antigen that is part of a membrane 
complex involved in the transduction of anti-proliferative and homotypic cell adhesion 
signals in lymphocytes.94 The IFITM proteins family includes IFITM1, 2 , 3, 4, 5 and 10 
which likely arose from an early gene duplication event in vertebrates. IFITM1, 2, 3 and 
5 are present in humans and are clustered in a 26kb region at the end of the short arm 
of chromosome 11, while IFITM10 is located closer to centromere and has an unknown 













persistent cytoplasmic DNA 
(virus, apoptosis),  






Figure 1.5 Proposed causes and results of endogenous IFN production by breast cancer 
  Stress response, persistent exposure to cytoplasmic DNA (DNA damaging chemicals, viruses) and 
loss of p53 function can all lead to endogenous type 1 IFN production through IRF7 induction. 
Chronic exposure to type 1 IFN leads to persistent JAK/STAT signaling and expression of ISGs that 




not an ISG, instead playing an important role in bone mineralization. The remaining 
IFITM proteins, IFITM1, 2 and 3, are potent inhibitors of viral entry and replication, with 
predominant expression on cell membranes in the endocytic pathway (Figure 1.6). 
IFITM proteins have very similar amino acid sequence with two transmembrane 
domains linked by a highly conserved intracellular loop (CIL).4,65 Several topologies 
have been proposed for IFITM protein conformation in cell membranes. The most 
Viruses enter cells by fusing with or penetrating a limiting cellular membrane. For most enveloped 
viruses fusion occurs either at the cell surface or, following uptake by endocytosis, from within 
endosomes. Trafficking through the endocytic system, from early to late endosomes, exposes 
virions to increasingly acidic environments. IFITM proteins (green) can inhibit entry, infection and 
replication by a number of viruses that fuse/penetrate at the cell surface or from within endosomes. 
IFITM1 is expressed primarily at the cell surface, while IFITM2 and 3 are primarily intracellular. 
IFITM3 has been localized to endosomal compartments, but the distribution of IFITM2 still needs to 
be clearly established. 
Figure 1.6 IFITM proteins inhibit virus entry at different stages of cell trafficking. 




current theory is that only one transmembrane domain spans the membrane, leaving 
the N-terminal and CIL on the inner leaflet and the C-domain on the outer leaflet (Figure 
1.7).9,62 This arrangement is consistent with highly conserved and palmitoylated 
cysteine residues that are present where the CIL and transmembrane proteins meet.1,9 
 In addition to inhibiting viral entry and replication, ISGs are also known to 
modulate the decision between cell survival and death.54,66,72,76 In fact, one study has 
found that the expression of ISGs increases in mouse models of endocrine resistant 
breast cancer.88 IFITM1 specifically is thought to promote the survival of epithelial cells 
and to allow breast, prostate, lung and brain cancer cells to survive chemotherapy and 
Panel (a) Topological models for IFITM proteins. (I) Represents an initial model for the proteins as 
transmembrane molecules with both the N-terminal and C-terminal domains (NTD and CTD) 
extracellular and the conserved intracellular loop (CIL) facing the cytoplasm.1 Subsequently, an 
alternative model (II) was proposed with the NTD, CTD and CIL all positioned intracellularly, and 
neither transmembrane domain (TMD1 and TMD2, green and purple respectively) spanning the 
bilayer.4 The most recent model (III) combines models I and II, positioning the NTD and CIL in the 
cytoplasm and the CTD extracellularly. Currently, the topology represented by III is only established 
for murine IFITM3.9 (b) Linear representation of human IFITM1, 2 and 3 showing key amino acids. In 
all cases, modifications and functional activities have only been established with IFITM3, but 
conserved residues in IFITM1 and 2 are shown. 
Figure 1.7 IFITM protein topology and domain organization. 
Smith et al. Current Opinion in Virology 2014, 4:71–77 
 
(I) (II) (III) 
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radiation.54,69,76 While the exact structure and functional domains of IFITM1 remain 
under study (Figure 1.7), recently identified binding partners include caveolin-1 (CAV-1) 
and CD81/TAPA-1. CAV-1 is a cell surface protein that is necessary to form 
invaginations in the cell membrane which impacts intracellular vesicle transport, cell 
cycle control and apoptosis. 95-97 CD81 is a member of the tetraspan family and is 
known to control proliferation, adhesion, and migration through association with many 
cell signaling molecules and transmembrane receptors.98-100  Both CAV-1 and CD81 
have been linked to cancer progression and metastasis.100-102 
Most recently there has been evidence to suggest that IFITM1 might also play a 
role in tumorigenesis. IFITM1 has been shown to be overexpressed in several types of 
cancers, including colorectal, gastrointestinal, head and neck, and breast, and its 
overexpression positively correlates with tumor progression and increased 
invasiveness.103-107 Our laboratory has previously shown that the IFN signaling pathway 
was activated in AI-resistant breast cancer cells as compared to AI-sensitive cell 
lines.46,108 Microarray analysis revealed that several ISGs, including IFITM1, were 
constitutively overexpressed in AI-resistant breast cancer cells.46 We hypothesize that 
IFITM1 overexpression contributed to the AI-resistant phenotype and promoted breast 




Due to the high incidence and poor-prognosis of AI-resistant breast cancer, there 
is a critical need to better understand the mechanism by which this phenomenon occurs 
so that alternative treatment options can be developed. Our overall research goal is to 
determine how breast cancer cells gain the ability to survive without estrogen. Notably, 
ISG expression is related to estrogenic signaling and the success of anti-estrogenic 
treatments. This thesis will demonstrate how alterations in the expression of one ISG, 
IFITM1, affect the phenotype of ER+ breast cancer cells. In this study, we validate the 
importance of IFITM1 overexpression using an in silico approach to mine several large 
datasets and then an in house retrospective study using tissue microarrays. We use 
IFITM1-null AI-sensitive MCF-7 and constitutively IFITM1-overexpressing AI-resistant 
MCF-7:5C cells to investigate the mechanism of IFITM1 overexpression in ER+ breast 
cancer cells. Gain and loss of function studies in MCF-7 and MCF-7:5C cells 
demonstrate the functional importance of IFITM1 expression.  
The information gained in this study has the potential to be exploited 
therapeutically due to both the discovery of novel drug targets and the addition of key 
ISGs to our developing profile of AI-resistant breast tumors. We hope that this profile 
can be used in the future to recognize which patients are good candidates for AI before 
initiating the treatment and to identify patients that have developed resistance long 
before a clinical recurrence of the tumor. We hypothesize that IFITM1 overexpression 
contributed to the AI-resistant phenotype and promoted breast cancer cell aggression 
and survival. We address this hypothesis in the following chapters: 
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Chapter 2: IFITM1 is overexpressed in breast cancer and is correlated with 
clinical outcome and response to therapy. In this chapter we analyze deposited 
tumor expression data to determine whether IFITM1 is expressed in breast cancer. We 
then use the Kaplan-Meier plotter and tissue microarrays to investigate the clinical 
significance of IFITM1 overexpression.109 
Chapter 3: Functional significance of IFITM1 overexpression in AI-resistant breast 
cancer. Here, we use gain and loss of function studies to investigate the functional 
impact of IFITM1 on the ER+ breast cancer cell phenotype including response to 
estrogen deprivation. In this chapter we assess the importance of IFITM1 expression in 
vitro and in two in vivo models of breast cancer. 
Chapter 4: Role of IFITM1 in controlling cell cycling and survival. We utilize 
inducible shRNA to knock down IFITM1 expression and determine the effect of IFITM1 
loss on survival with particular attention given to the cyclin dependent kinase inhibitor 
p21. 
Chapter 5: Regulation of IFITM1 by JAK/STAT signaling in AI-resistant breast 
cancer. In this chapter we examine the mechanisms of IFITM1 overexpression 
including JAK/STAT signaling and ER mediated mucin 1 expression. We then analyze 
the motifs in the IFITM1 promoter that STAT protein complexes use to drive IFITM1 
transcription. Finally, we investigate the feasibility of targeting IFITM1 with the JAK1/2 
inhibitor ruxolitinib in vivo. 
 Chapter 6: Conclusion. Summary of results, a discussion on how this research 
contributes to the field and suggestions for future directions of this work. 
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CHAPTER 2 : IFITM1 IS OVEREXPRESSED IN BREAST CANCER AND IS 
CORRELATED WITH CLINICAL OUTCOME AND RESPONSE TO THERAPY 
This chapter is adapted from: 
 
Choi HJ & Lui A, Ogony J, Jan R, Sims P, Lewis-Wambi J. Targeting interferon 
response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-
induced cell death. Breast Cancer Res, 2015. 17(1): p. 6. PMCID:4336497. 
 
Lui A, Ogony J, Geanes E, Behbod F, Valdez K, Marquess J, Jewell W, Tawfik O, 
Lewis-Wambi J. IFITM1 suppression blocks proliferation and invasion of aromatase 
inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21. Cancer 
Lett. 2017 Apr 12;399:29-43.  
  
INTRODUCTION 
Approximately 30% of estrogen receptor expressing (ER+) breast tumors are 
resistant to anti-hormonal treatment. 26 In addition, as many as 40% of women 
successfully treated with aromatase inhibitors (AIs) eventually develop resistance to this 
therapy over time. 30 The ensuing cancer cells are capable of long term estrogen-
independent survival and proliferation. Many potential methods for maintaining 
estrogen-independent growth are available but the true mechanism(s) of aromatase 
inhibitor-resistance remains unclear. Previous studies have focused on alterations in 
estrogen receptor (ER) signaling, as well as non-estrogenic processes including those 
that regulate cell survival, the cell-cycle, and receptor tyrosine kinase activity. 29,30,110 
Our lab has reported the development of an AI-resistant breast cancer model that 
exhibits constitutive overexpression of type-1 interferon (IFN) stimulated genes (ISGs).  
The type-1 IFN cytokine family includes IFNα and β. They mediate danger 
signaling in the immune system by binding the type 1 IFN receptor (IFNAR) and 
stimulating JAK/STAT signaling through a phosphorylation cascade that promotes the 
expression of hundreds of ISGs. The ISGs protect from viral infection by preventing viral 
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entry and replication as well as promoting the survival of adjacent uninfected cells. 58 
Despite the positive role of JAK/STAT signaling and the ISGs in the immune system, 
they have also been implicated in the pathogenesis of some cancers. While it has not 
been studied in breast cancer, the ISGs interferon transmembrane protein 1 (IFITM1) 
has been linked to the progression of several aggressive cancer types, including 
cancers of the cervix, esophagus, colon, ovary and brain.77,95,101,105,106,111-113  
IFITM1 is a 17-kDa transmembrane protein coded on the short arm of 
chromosome 11.62 It belongs specifically belongs to a group of ISGs that are produced 
in response to lower levels of type 1IFNs, and are thought to promote cancer 
progression and DNA damage resistance.54,76,95,101,105,114,115 We began our study by 
determining whether IFITM1 was indeed expressed in breast cancer and whether it held 




IFITM1 is overexpressed in breast cancer 
To determine whether IFITM1 was expressed in breast cancer we used the 
Oncomine database to compare IFITM1 expression in invasive ductal carcinoma (IDC) 
and normal breast tissue in four deposited datasets (Figure 2.1).  Analysis of 201 IDC 
and 24 normal breast samples revealed that IFITM1 is significantly overexpressed in 
IDC as compared to normal breast tissue. In the four analyzed datasets, IFITM1 had a 
median gene rank of 77 putting it in the top 1-5% of all genes altered in IDC. This result 
indicates that IFITM1 is indeed a gene significantly upregulated in breast cancer.  
IFITM1 is overexpressed in AI-resistant breast cancer  
We investigated the clinical significance of IFITM1 expression in AI-resistant 
(recurrence) breast cancer by performing IHC staining on normal breast tissue, primary 
breast tumors (N = 40) and AI-resistant recurrence breast tumors (N = 40). We found 
that IFITM1 proteins was overexpressed in 90% of the AI-resistant (recurrence) tumors 
(36 of 40 samples) compared with only 20% of the primary tumors (8 out of 40 
samples); however, in normal breast tissue IFITM1 was undetectable (Figure 2.2). As 
shown in Table 2.1, stained slides were scored in terms of intensity and distribution. 
Normal breast tissue showed no staining for IFITM1 (SI score = 0); primary tumors 
showed medium staining for IFITM1 and PLSCR1 which correlated with low expression 
(SI score of ≤3); and AI-resistant (recurrence) tumors showed very strong staining for 
IFITM1 which correlated with high expression of both proteins (SI score of ≥6). Taken 
together, these results demonstrate that interferon regulated genes are constitutively 
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overexpressed in AI resistant breast cancer and they suggest that interferon signaling 
might be dysregulated in the resistant cells. 
  
(A) Relative expression of IFITM1 in normal and invasive ductal carcinoma (IDC) from four Oncomine 
breast cancer datasets is shown on a log2 scale allowing for comparison of fold change in expression. 
(B) Pooled analysis of relative IFITM1 expression in all four Oncomine datasets using a log rank 
analysis places IFITM1 in the top 3% of genes most upregulated in breast cancer as compared to 
normal breast tissue. 
 
Figure 2.1 IFITM1 is overexpressed in breast cancer. 





Immunohistochemistry (IHC) staining for IFITM1 was performed on tissue microarrays generated from 
normal breast tissue (left panel), primary breast tumor tissue (middle panel) and recurrence breast 
tumor tissue (right panel). For immunohistochemical analysis, the scores were determined by combining 
the proportion of positively stained tumor cells and the intensity of staining, giving rise to a Staining 
Index (SI) value for each sample. The proportion of positively stained tumor cells was graded as follows: 
0 (<5% positively stained tumor cells), 1 (5% to 25% positive tumor cells), 2 (25% to 50% positive tumor 
cells), 3 (50% to 75% positive tumor cells) and 4 (>75% positive tumor cells). Representative 
photomicrographs were taken using a phase-contrast microscope (original magnification, ×200). 






Normal Primary Resistant 
N=0/10 N=8/40 N=36/40 





   
Normal tissues   No stain 10/10 
Weak      0/10    
 Strong    0/10 
Primary tumors   No stain 32/40    
     Weak   8/40    
     Strong     0/40 
Recurrence tumors  No stain 0/40    
     Weak     4/40    
     Strong    36/40 
Staining 
Intensity IFITM1 
Table 2.1 Staining intensity for IFITM1 expression in AI-resistant TMA 





Table 2.3 IFITM1 staining intensity in normal and cancerous breast tissues 
Table 2.2 Distribution of clinical and histologic parameters in 
ER+ invasive ductal carcinoma samples 
Lui et al. Cancer Letters. 2017 Apr 12;399:29-43 
Lui et al. Cancer Letters. 2017 Apr 12;399:29-43 
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High IFITM1 expression is correlated with poor clinical outcome 
Since 20% of our primary breast tumors expressed IFITM1, we next investigated 
whether high IFITM1 expression at the time of diagnosis was correlated with clinical 
outcome in ER+ breast cancer. We examined the overall survival for patients with grade 
1 ER+ breast cancer using the Kaplan-Meier Plotter breast cancer survival database 
and found that high IFITM1 expression correlated with poor overall survival (Figure 
2.4A).109  We next conducted in-house analysis of IFITM1 expression in 94 ER+ breast 
cancer patient samples using immunohistochemistry. The patients included in this study 
represented typical patient demographics with an average age of 58.3years. The 
patients were 91% European American, had mostly stage 1 and 2 disease and were 
predominately Her2/neu negative (Table 2.2). The 94 samples represented the full 
range of IFITM1 expression (0-3) (Figure 2.3) and all of the normal breast tissue 
samples were negative for IFITM1 expression (Table 2.3). High IFITM1 intensity score 
was correlated with decreased survival but also increased clinical stage and risk of 
recurrence during endocrine therapy (Figure 2.4). These two separate analyses suggest 
that high IFITM1 expression in ER+ breast cancer is significantly associated with poor 





Immunohistochemical staining for IFITM1 expression was conducted in 94 ER+ breast cancer patient 
samples and 6 normal breast tissue samples. Staining intensity was graded on a scale of 0-3 with 
representative images of each staining intensity shown. 

































Lui et al. Cancer Letters. 2017 Apr 12;399:29-43 
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(A) The hazard ratio (HR) and 95 % confidence interval for high IFITM1 expression in ER+ Luminal A 
breast cancer patients was analyzed using The Kaplan-Meier Plotter database. P-value was 
determined by log-rank test. Immunohistochemical staining for IFITM1 expression was conducted in 
94 ER+ breast cancer patient samples and 6 normal breast tissue samples. Staining intensity was 
graded on a scale of 0-3. IFITM1 staining intensity was correlated with patient survival (B) clinical 
stage (C) and recurrence (D). *p < 0.05, ** p< 0.01 
 
Figure 2.4 IFITM1 overexpression is correlated with poor clinical outcome. 




We had previously reported high IFITM1 expression in AI-resistant breast cancer 
cell lines. Here, we found that this observation was clinically relevant using in silico 
analysis of deposited patient gene expression data. Notably, we found that there is no 
IFITM1 expression in normal breast tissue. It is thought that IFITM1 can drive the 
progression of several types of cancer but it had not been previously investigated in the 
breast. The IFN signaling pathway may be one of the strategies used by cancer to 
overcome normal restrictions on proliferation and survival. The fact that IFITM1 is 
actually expressed in breast cancer allowed us to next assess whether IFITM1 
expression had any clinical significance. Stratification of the oncomine datasets by 
Luminal A and Luminal B breast cancer would provide an interesting comparison of 
IFITM1 expression in different subsets of ER+ breast cancer and would strengthen this 
study. 
In our tissue microarrays revealed that AI-resistant tumors express significantly 
higher levels of IFITM1 than even the original tumor prior to AI therapy. This data 
suggests that estrogen starvation may drive IFITM1 expression. Cross-talk between the 
type1 IFN-signaling pathway and ER has been speculated due to the critical role of 
IRF1 in modulating the effects of anti-estrogen therapy. 85,86 Thus far a positive 
regulatory feedback loop between the IFNs and ERα has been discovered, which opens 
the possibility that the IFNs can promote breast cancer progression by enhancing 
estrogen signaling. 116 Conversely, 17b-estradiol has been shown to induce IFNα 
production by macrophages, closing the feedback loop between the mammary gland 
macrophages in the tumor microenvironment.117 It is probable that the interaction 
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between ER and IFN signaling has implications for breast cancer development and 
prognosis. Recently, the expression of several cytokine receptors, including IFNAR2 
has been associated with breast cancer risk in patients 118 and the expression of a type 
I IFN gene signature by mammary epithelial cells has been shown to vary by hormonal 
status in two strains of mice, with the strongest ISG expression occurring during 
diestrous when estrogen levels are the highest.119 Additionally, the estrogen-responsive 
gene mucin1 (MUC1) is frequently upregulated in breast cancer due its ability to prevent 
apoptosis and is also a known stabilizer of STAT1 phosphorylation in breast cancer 
cells. 67,120,121 Further study into the collaboration between estrogen and IFN signaling is 
likely to yield new targets for prevention and therapy.  
Since we found that IFITM1 overexpression could be found in some primary 
tumors, we also investigated whether IFITM1 expression could predict clinical outcome 
or response to endocrine therapy. In a retrospective clinical trial of ER+ breast tumors 
we found that high IFITM1 expression was associated with not only overall survival but 
also clinical stage and risk of recurrence during endocrine therapy. These results 
support the idea that IFITM1 expression could be used to screen ER+ breast cancer 
patients for responsiveness to endocrine therapy and may define a resistant subset. In 
this study ER, PR and Her2 scoring was conducted by the Department of Pathology and 
Laboratory Medicine at the time of patient diagnosis. We did not independently confirm 
ER expression in our tumors, which would strengthen our study. Additionally, 
assessment of the percentage of proliferation with Ki67 staining would allow us to 
determine whether IFITM1 expression correlates with other markers of aggressive 
breast cancer currently used in the clinic. In future, including other ISGs that are also 
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overexpressed in AI-resistant breast cancer to generate a panel of genes that can 
define this resistant subset would likely be more clinically useful and could better predict 




MATERIALS AND METHODS 
AI-resistant TMA 
Paraffin-embedded de-identified human breast cancer tissue samples were collected 
from the Tumor Bank facility at The Research Institute of Fox Chase Cancer Center 
(Philadelphia, PA, USA) and the University of Kansas Medical Center (KUMC) and the 
protocols were reviewed and approved by the Institutional Review Board at Fox Chase 
Cancer Center and KUMC. The archived tumor samples were collected from patients (N 
= 40) who were initially treated with Arimidex and either responded or responded but 
then developed recurrence disease with an average time to disease progression (TTP) 
of 93 months. Patients provided written informed consent for the use of their tumor 
samples. Tissue microarray (TMA) slides were constructed from 40 matching primary 
and AI-resistant tumors using duplicate cores of 0.6 mm per tumor sample. Normal 
mammary tissue samples (N = 10) were also included on the TMA. For 
immunohistochemistry assays, tissue microarray slides were incubated at room 
temperature for 20 minutes with antibodies against IFITM1 (Santa Cruz Biotechnology) 
and PLSCR1 (Chemicon Inc.) applied at 1:100 dilution in antibody diluent (Dako, 
Carpenteria, CA, USA). A secondary anti-mouse antibody polymer conjugated with HRP 
(Dako) was applied for 30 minutes and 3,3-diaminobenzidine(DAB) was used to 
produce visible, localized staining viewable with light microscopy. Sections without 
primary antibody served as negative controls. A semi-automated quantitative image 
analysis system, ACIS II (ChromaVision Medical Systems, Inc., San Juan Capistrano, 
CA, USA), was used to quantitate the staining of the TMA slides. For 
immunohistochemical analysis, the scores were determined by combining the 
proportion of positively stained tumor cells and the intensity of staining, giving rise to a 
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Staining Index (SI) value for each sample. The proportion of positively stained tumor 
cells was graded as follows: 0 (<5% positively stained tumor cells), 1 (5% to 25% 
positive tumor cells), 2 (25% to 50% positive tumor cells), 3 (50% to 75% positive tumor 
cells) and 4 (>75% positive tumor cells). The intensity of staining was recorded on a 
scale of 0 (no staining), 1 (weak staining, light brown), 2 (moderate staining, yellowish 
brown) and 3 (strong staining, brown). The SI value was calculated as follows: SI = 
staining intensity × proportion of positively stained tumor cells. Scores were evaluated 
comparatively for the expression of IFITM1 and PLSCR1 in breast tumors by SIs 
(scored as 0, 1, 2, 3, 4, 6 or 9). An optimal cutoff value was identified, and the SI score 
of ≥6 was used to define tumors with high expression and SI ≤3 as tumors with low 
expression of IFITM1 and PLSCR1. 
Survival analysis 
Survival data were obtained from the Kaplan-Meier Plotter 2014 breast cancer survival 
database (http://kmplot.com/analysis/index.php?p=service&cancer=breast).109 The 131 
patients with grade 1 ER+ disease as determined by gene expression data were 
included in the analysis. Patients were stratified by IFITM1 expression (probe set 
214022_s_at) relative to median. The P-value was calculated using a log-rank test. 
ER+ Tissue Microarray and IHC data analysis 
This retrospective study was approved by the Institutional Review Committee at the 
University of Kansas Medical Center (KUMC). A total of 94 primary ER+ invasive ductal 
carcinomas diagnosed and removed surgically between 2001 and 2010, and for whom 
follow-up information was available, were examined. Samples were taken from 6 normal 
breast tissue samples from routine reduction mammoplasties were also examined. 
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These tissues were formalin-fixed and paraffin-embedded (FFPE). Clinicopathological 
data including age, race, clinical stage and Her2 staining are shown in Table 1. At 
diagnosis, tissue blocks containing the most representative and well-preserved tumor 
areas were selected for IHC. IHC analysis was performed on tissue fixed with 10% 
neutral buffered formalin. IHC analyses for ER was performed at the time of diagnosis 
on all specimens in the Department of Pathology and Laboratory Medicine at KUMC. 
Samples with greater than 1% of the tumors staining for ER were considered positive 
and qualified the sample to be included in the tissue microarray. After review of the 
hematoxylin and eosin slides and marking of tumor areas, 2-mm tissue cores of 
representative tumor areas were extracted and inserted in recipient blocks. IHC analysis 
for IFITM1 (Santa Cruz) was performed on tissue microarrays obtained from the same 
samples (see IHC Staining protocol below). Two cores from each tumor were analyzed 
in an attempt to account for the impact of tumor heterogeneity on IFITM1 expression. 
IFITM1 staining intensity was quantified manually on a scale of 0-3 where 0 means no 
staining, 1+ is faint staining, 2+ is moderate staining and 3+ is strong staining. Cores 
were scored by three independent individuals prior to accessing patient medical 
records. Final distribution of IFITM1 expression is shown in Table 2. Histopathologic 
parameters were extracted from patient pathology records and clinical parameters were 
obtained from electronic medical records.  
IHC staining was performed after tissue deparaffinization by clearance in xylene and 
hydration through graded ethanol series. Antigen retrieval was conducted at 99˚C in 
Dako Target retrieval solution (S1700) for 20 min per manufacturer’s instructions 
(Agilent Technologies, Copenhagen, Denmark). For human samples, blocking was 
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performed using 5% normal horse serum and antibody dilution was performed in 0.01% 
Triton-X. For mouse xenografts, blocking and antibody dilution were performed using 
the Mouse on Mouse (MOM™) Kit following manufacturer’s instructions (Vector Labs, 
Burlingame, CA). Sections were stained using primary human antibodies targeted 
against IFITM1, ERα, phospo-STAT1 (ser701), CD31, MMP1 (Santa Cruz) and Ki67 
(Dako) and HRP-conjugated biotinylated secondary antibodies (Vector Labs). 
Immunoperoxidase signal was produced using 3,3’-Diaminobenzidine (DAB) and 
amplified using the Vectastain® Elite ABC Kit (Vector Laboratories). Tissue sections 
were counter stained using hematoxylin and mounted in xylene. Slides were imaged on 






CHAPTER 3 : FUNCTIONAL SIGNIFICANCE OF IFITM1 OVEREXPRESSION IN AI-
RESISTANT BREAST CANCER  
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response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-
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Lewis-Wambi J. IFITM1 suppression blocks proliferation and invasion of aromatase 
inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21. Cancer 
Lett. 2017 Apr 12;399:29-43.  
 
INTRODUCTION 
To investigate the role of altered ISG expression in AI-resistance, we will use our 
previously described model of endocrine-resistant breast cancer.42 Briefly, MCF-7 cells, 
which require estrogen for proliferation and survival, were starved long-term through the 
depletion of estrogen from their serum and utilization of phenol-free media. After many 
rounds of selection for an estrogen-independent phenotype, the clone MCF-7: 5C was 
established.122 The MCF-7:5C cell line maintains fully functional wild type ER and grows 
robustly without estrogen; however MCF-7:5C cells proliferate more quickly and are 
more invasive than MCF-7 cells in vitro and in vivo.108 A unique feature of the MCF-7:5C 
cells is their constitutive overexpression of a panel of genes associated with 
inflammation and inflammatory signaling. Here we use the AI-resistant MCF-7:5C and 
AI-sensitive MCF-7 cell line to investigate the role of IFITM1 in AI-resistance. 
In vivo mouse models are the most common tool used for investigating the 
clinical relevance of breast cancer studies. Traditionally, the orthotopic model is used to 
evaluate tumor growth. The breast cancer cells are injected directly into the mammary 
fat pad and allowed to grow over time, allowing for assessment of proliferation, cell 
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death, and/or metastasis. Breast cancer, however, originates inside the mammary duct 
where the cells must invade out of the duct prior to establishing a solid tumor. The 
mouse mammary intraductal (MIND) model has been developed to study breast cancer 
cell invasion in vivo.123,124 In this model, breast cancer cells are injected into the 
mammary duct through the nipple, where they populate the duct and can invade into the 
surrounding mammary gland. The MIND model provides a tumor microenvironment that 
permits the in vivo study of previously difficult to grow ER+ breast cancer cell lines and 
faithfully mirrors the behavior of primary breast cancer cells in patients with regard to 
aggression and response to therapy.125 The orthotopic model tests the proliferation and 
survival of tumor cells in vivo, modeling an established tumor of several million cells. In 
comparison, the MIND model more faithfully replicates the early stages of breast cancer 
development, where a small number of abnormal cells begin to proliferate inside of the 
duct and eventually gain the ability to bypass the basement membrane and invade into 
the mammary gland. The MIND model allows for analysis of proliferation and survival 
but also the investigation of breast cancer invasion and the early stages of the 
metastatic cascade. In this chapter we establish clones of the MCF-7 and MCF-7:5C 
cell line with altered IFITM1 expression and use both the orthotpic and MIND models to 







IFITM1 is constitutively overexpressed in AI-resistant human breast cancer cells 
Microarray studies previously revealed that the interferon signaling pathway was 
altered in AI-resistant breast cancer cells compared with AI-sensitive cells.46 To validate 
our microarray data we measured the basal expression of two well-known interferon 
stimulated proteins, IFITM1 and PLSCR1, in AI-resistant MCF-7:5C breast cancer cells 
and AI-sensitive MCF-7 cells. Our data showed that IFITM1 was constitutively 
overexpressed at the protein (Figure 3.1A) and mRNA level (Figure 3.1B) in AI-resistant 
MCF-7:5C cells but were almost undetectable at the protein and mRNA level in AI-
sensitive MCF-7 cells. Notably, we also found that several other ISGs including 
PLSCR1, IFI27, IFIT1, OAS1, MX1, STAT1 and STAT2 were constitutively 
overexpressed in AI-resistant MCF-7:5C cells compared with MCF-7 cells (Figure 3.1C).  
Loss of IFITM1 induces the death of aromatase inhibitor-resistant breast cancer cells.  
To assess the functional significance of IFITM1 overexpression in AI-resistant 
MCF-7:5C breast cancer cells, we used three siRNAs (siIFITM1A, siIFITM1B, 
siIFITM1C) to silence its expression (Figure 3.2A). We found that all three siRNAs 
completely reduced IFITM1 expression in MCF-7:5C cells and that loss of IFITM1 
resulted in cell death which was quantified using AnnexinV/PI staining and TUNEL 
staining (Figure 3.2B and Figure 3.2C). To further investigate the effects of IFITM1 loss 
on proliferation and death in AI-resistant cells, we developed the MCF-7:5C/shIF cell 
line which expresses IFITM1 shRNA under the control of a tetracycline/doxycycline-
inducible promoter. Our lentivirus-inducible system showed that upon doxycycline (Dox) 
exposure, IFITM1 expression was reduced in MCF-7:5C/shIF cells in a concentration-
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dependent manner, with maximum reduction at 1 μg/mL Dox (Figure 3.2D). Consistent 
with our siRNA in vitro data, loss of IFITM1 using Dox-inducible shRNA initiated cell 
death over time, with maximal response after 96 hours, as demonstrated by PARP 
cleavage (Figure 3.2D) and annexin-PI staining (Figure 3.2E). Notably, Dox treatment 
had no effect on the survival of un-transduced MCF-7:5C cells or MCF-7:5C cells 
expressing a scrambled control vector (MCF-7:5C/shCon) (Figure 3.2F). These data 
demonstrate that IFITM1 overexpression enhances the growth of AI-resistant MCF-7:5C 
cells and that silencing IFITM1 expression using siRNAs/shRNAs inhibits proliferation 
and induces death in these cells.  
 
Loss of IFITM1 inhibits AI-resistant breast tumor growth and promotes cell death in vivo. 
Generation of the MCF-7:5C/shCon and MCF-7:5C/shIF cells allowed us to 
assess the effect of IFITM1 loss on the growth of MCF-7:5C cells in vivo. MCF-
7:5C/shCon and MCF-7:5C/shIF cells were implanted into the 4th mammary fat pad of 
ovariectomized NOD scid gamma (NSG) mice. After 10 days, mice were randomized to 
Dox (+ Dox) or vehicle (- Dox) treatment for 22 days. We found that Dox exposure 
significantly reduced MCF-7:5C/shIF tumor growth compared to the –Dox group (vehicle 
control) (Figure 3.3A and Figure 3.3B) and that the reduction in tumor growth positively 
correlated with a loss of IFITM1 expression and a decrease in the proliferation marker 
Ki67 (Figure 3.3C). TUNEL staining of MCF-7:5C/shIF tumors confirmed that the 
reduction in tumor growth in the Dox-treated group was due to cell death/apoptosis 
(Figure 3.3C) Notably, Dox exposure had no effect on the growth of MCF-7:5C/shCon 
cell tumors (Supplemental Figure 3.1A) or on the expression of IFITM1, Ki67 or TUNEL 
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(Supplemental Figure 3.1B). This data confirm that IFITM1 overexpression is important 
for the growth and survival of AI-resistant MCF-7:5C tumors in vivo. 
  
(A) Whole cell lysate from MCF-7 and MCF-7:5C cells was immunoblotted for IFITM1, PLSCR1 
protein expression. Total RNA was extracted from MCF-7 and MCF-7:5C cells and mRNA expression 
for (B) IFITM1 and PLSCR1, IFIT27, IFIT1, OAS1, STAT2 and STAT2 (C) was determined by real-
time PCR. Fold change is reported relative to MCF-7 expression. 
 
 
Figure 3.1 ISGs are overexpressed AI-resistant MCF-7:5C cells 





(a) Cell lysates from MCF-7:5C cells transfected with scrambles control siRNA (siCon) or three 
different IFITM1 siRNA sequences (siIFITM1 A, B, C) were immunoblotted for IFITM1 expression. (b) 
Dual annexin/PI staining was used to quantify cell death in each transfection group. Data represent 
means ± SD from two experiments conducted in duplicate. (c) MCF-7:5C cells were transiently 
transfected with siCon or siIFITM1C. The intensity of TUNEL (red) staining was used to assess the 
effect of IFITM1 knockdown on cell survival and was quantified using five separate images with Image 
J Software (right panel). (d) MCF-7:5C/shIF cells were treated with the indicated concentrations of 
doxycycline to induce IFITM1 shRNA expression. IFITM1 and PARP protein expression levels were 
determined by immunoblotting. (e) MCF-7:5C/shIF cells were treated with 10μg/mL doxycycline over a 
118 hour period. Annexin V/ Propidium Iodide staining quantified the percent of dead cells over the 
accompanying untreated (control) sample. (f)MCF-7:5C, MCF-7:5CshCon and MCF-7:5C/shIF cells 
were treated with 1ug/mL Dox and the percent dead cells determined by Annexin V/PI staining. Data 
represents two independent experiments conducted in duplicate. * p<0.05 ** p< 0.01 
 
Figure 3.2 Loss of IFITM1 induced death in AI-resistant MCF-7:5C cells. 




(a) 3 million MCF-7:5C/shIF cells were injected into the 4th mammary fat pad of ovariectomized 
female NSG mice. 9 days after orthotopic injection, mice were randomized to treatment groups and 
half were provided doxycycline (Dox)-treated drinking water. Tumors were measured by digital 
calipers and tumor volume (mm3) displayed over time. (b) At the end of the experiment tumors were 
excised and are shown. Tumor volumes were determined by digital caliper measurement. (c) 
IFITM1 and Ki67 expression was determined by immunohistochemical staining. The percent of Ki67 
positive cells was determined by counting four separate 40X fields. Cell death was analyzed by 
TUNEL staining and quantified by Image J software. ** p< 0.01 
Figure 3.3 Loss of IFITM1 inhibited MCF-7:5C tumor growth and promoted cell 
death in vivo. 
Lui et al. Cancer Letters. 2017 Apr 12;399:29-43 
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Loss of IFITM1 blocks aromatase inhibitor-resistant tumor cell invasion out of the 
mammary duct. 
Since our previous studies indicated that loss of IFITM1 inhibited cell invasion in 
vitro, we used the mammary intraductal (MIND) model of breast cancer to investigate 
the effect of reduced IFITM1 expression on AI-resistant tumor cell invasion in vivo 
(Figure 3.4) 59,73. After three weeks of Dox exposure, we confirmed that the MIND model 
was able to accurately assess tumor cell invasion out of the mammary duct using 
immunofluorescent staining (Figure 3.5A). Immunofluorescent staining verified that Dox 
exposure resulted in IFITM1 loss in the MIND model (Figure 3.5A). Smooth muscle 
actin (SMA) was used to stain the myoepithelial layer of the mammary duct and human 
keratin 19 (K19) was used to label the breast cancer cells (Figure 3.5A). Hematoxylin 
and eosin (H&E) staining further revealed the architecture of the mammary glands, 
demonstrating that invasive IFITM1-expressing cells breach the mammary duct and 
A diagram of the two breast cancer models where cells are injected into the mammary fat pad 
(Orthotopic Model) or through the nipple (MIND Model). 
Figure 3.4 A comparison of the orthotopic and MIND models of breast cancer. 




invade into the mammary gland stroma (Figure 3.5B). Immunohistochemical staining for 
SMA was used to visualize the extent of tumor burden in the mammary gland 
parenchyma (Figure 3.5B) and to quantify the extent of invasion (Lesions/Duct) (Figure 
3.5C). The MIND model revealed that MCF-7:5C/shIF cells were highly invasive, 
however, loss of IFITM1 (+Dox) completely blocked the ability of these cells to invade 
out of the mammary duct as demonstrated by the lack of K19-stained cells outside of 
the duct (Figure 3.5A and Figure 3.5C).  Using Ki67 and TUNEL staining, we found that 
loss of IFITM1 expression also reduced cell proliferation and increased cell death in the 
MIND model of breast cancer (Figure 3.6). This experiment demonstrates that the MIND 
model can be used to assess the impact of individual gene expression on ERα+ tumor 
cell invasion in vivo and that it faithfully replicates effects on cell survival and 
proliferation seen in vitro or the orthotopic model of breast cancer. 
Immunohistochemistry staining verified that Dox exposure resulted in IFITM1 
loss in the MIND model. Hematoxylin and eosin (H&E) staining further revealed the 
architecture of the mammary glands, demonstrating that invasive IFITM1-expressing 
cells breach the mammary duct and invade into the mammary gland stroma. When 
IFITM1 expression is lost, breast cancer cells remain confined within the duct and the 
majority of the stoma is comprised of adipose tissue (Figure 3.6B). Using Ki67 and 
TUNEL staining, we found that loss of IFITM1 expression reduced cell proliferation and 
increases cell death in the MIND model of breast cancer (Figure 3.6B). Dox exposure 
had no effect on the invasion, proliferation or survival of MCF-7:5C/shCon cells in either 
in vivo model (Supplemental Figure 3.2). Interestingly, we also found that the MIND 
model maintains higher estrogen receptor α (ERα) expression than the orthotopic model 
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5,000 MCF-7:5C/shIF cells were injected into the duct of the 4th mammary gland of female 
ovariectomized NSG mice use the MIND injection protocol. After 10 days, mice were randomized to 
treatment groups and half were provided doxycycline (Dox)-treated drinking water. After 3 weeks, 
mammary glands were removed. (a) Mammary glands were fixed and processed onto glass slides. 
Immunofluorescent staining of the breast cancer cells for IFITM1, human keratin 19 (HuK19-red) and the 
mammary duct for smooth muscle actin (SMA-green) was conducted. Arrows indicate the mammary 
duct wall. (b) The milk duct was identified by immunohistochemistry. SMA was used to delineate 
invasive areas at 10X (upper panel) and 20X (lower panel). (c) Number of invasive lesions were 
quantified per duct in a 10X field. Numbers represent averages of 5 fields in 3 different mammary glands 
for each treatment group. ** p< 0.01 
Figure 3.5 Loss of IFITM1 reduced aromatase inhibitor-resistant tumor cell invasion in 
the MIND model. 
Lui et al. Cancer Letters. 2017 Apr 12;399:29-43 
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for both MCF-7 and MCF-7:5C cells (Supplemental Figure 3.3). This experiment 
demonstrates that the MIND model can be used to assess the impact of individual gene 
expression on ERα+ tumor cell invasion in vivo and that it faithfully replicates effects on 
cell survival and proliferation seen in vitro or the orthotopic model of breast cancer. 
(a) H&E, IgG (negative staining control) and IFITM1 staining in MIND injected mammary glands from 
untreated and doxycycline (Dox) treated mice. (b) Immunofluorescent staining for Ki67 on these 
glands is shown (left panel) and quantified (right panel). The percent of Ki67 positive cells was 
determined by counting five separate 40X fields. Cell death was analyzed by TUNEL staining and 
quantified by Image J software. ** p< 0.01 
Figure 3.6 Loss of IFITM1 decreased cell proliferation and increased cell death in the 
MIND model of breast cancer. 
Lui et al. Cancer Letters. 2017 Apr 12;399:29-43 
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Overexpression of IFITM1 promotes breast cancer cell aggression in vitro and in vivo.  
To validate the importance of IFITM1 in the ER+ breast cancer cell phenotype, 
we overexpressed IFITM1 in parental MCF-7 cells using CRISPR/Cas9 guided 
transcription. Two clones, MCF-7/IF-1 and MCF-7/IF-2 were generated which 
expressed moderate and high levels of IFITM1 respectively (Figure 3.7A), as compared 
to control scrambled guiding-RNA expressing MCF-7/C9Con cells which lack IFITM1. 
IFITM1 overexpression enhanced MCF-7 cell proliferation in a 96 hour cell viability 
assay (Figure 3.7B). Additionally, IFITM1 overexpression enhanced the aggressive 
phenotype and tumorigenic potential of MCF-7 cells as demonstrated by soft agar 
anchorage-independent growth (Figure 3.7D) and wound healing cell migration assays 
(Figure 3.7E). To determine whether IFITM1 overexpression contributes directly to AI-
resistance, we cultured the MCF-7/IF clones (MCF-7/IF1 and MCF-7/IF2) in estrogen-
deprived conditions to mimic  AI treatment, and we found that overexpression of IFITM1 
in MCF-7 cells increased their proliferation, tumorigenicity, and estrogen-independent 
growth  (Figure 3.7C) compared to MCF-7 and MCF-7/C9Con cells (Supplemental 
Figure 3.4). 
  To assess the role of IFITM1 overexpression in vivo, we transplanted the MCF-
7/C9Con, MCF-7/IF-1 and MCF-7/IF-2 cells into intact (not ovariectomized) female NSG 
mice using both the orthotopic and MIND models of breast cancer. Overexpression of 
IFITM1 resulted in the enhanced growth of MCF-7/IF-2 solid tumors (Figure 3.8A and 
Figure 3.8B). Immunohistochemistry revealed that the MCF-7/IF-2 tumors continued to 




(a) IFITM1 expression in MCF-7 cells expressing scrambled control (MCF-7/C9Con) or an IFITM1 
guided Cas9 overexpression vector (MCF-7/IF-1 and MCF-7/IF-2) was determined by immunoblotting 
and compared to expression in MCF-7:5C cells. (b) The proliferation of parental MCF-7, MCF-
7/C9Con and MCF-7/IF-2 cells in estrogen containing media was measured over 96 hours by Cell 
Viability assay. (c) A direct comparison of proliferation in estrogen and estrogen free media is shown 
at 96 hours. (d) MCF-7/C9Con and MCF-7/IF-2 were subjected to soft agar anchorage independent 
growth assay. Plates were imaged after 21 days and the number of colonies was quantified using 
Image J (lower panel). Values represent two independent experiments conducted in duplicate. (e) 
Scratch assay was conducted on 70 % confluent plates of MCF-7/C9Con and MCF-7/IF-2 cells. Plates 
were imaged at 0, 24 and 48 hours and the size of the wound was quantified by image J (right panel). 
Values represent two independent experiments conducted in triplicate. *p < 0.05, ** p< 0.01 
Figure 3.7 Overexpression of IFITM1 enhances the aggressive phenotype of MCF-7 
breast cancer cells in vitro. 





(a) Intact female NSG mice were orthotopically injected with MCF-7/C9Con and MCF-7/IF-2 cells and 
tumors measured by digital calipers weekly. Tumor volume (mm3) was calculated and charted over 
time.  (b) The tumors were excised and imaged at day 56 and final tumor volume (mm3) determined. 
(c) IFITM1 and Ki67 expression was determined by immunohistochemical staining. The percent of 
Ki67 positive cells was determined by counting four separate 40X fields (lower panel). (d) Intact 
female NSG mice were injected with MCF-7/C9Con and MCF-7/IF-2 cells using the MIND model. 
Smooth muscle actin (SMA) staining by immunohistochemistry elucidated the milk duct. Arrow heads 
indicate invasive lesions which were quantified per duct in a 10X field. Numbers represent averages of 
5 fields in 3 different mammary glands for each group (lower panel). *p < 0.05, ** p< 0.01 
Figure 3.8 Overexpression of IFITM1 promoted breast cancer cell proliferation and 
invasion in vivo. 
Lui et al. Cancer Letters. 2017 Apr 12;399:29-43 
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MCF-7/IF-2 cells were significantly more invasive than MCF-7/C9Con cells. We found 
that IFITM1 overexpression increased angiogenesis in MCF-7 xenografts 
(Supplemental Figure 3.4). Similar results were seen in moderately IFITM1-
overexpressing MCF-7/IF-1 cells (Supplemental Figure 3.4), further demonstrating that 
IFITM1 expression alone can promote the proliferation, migration and invasion of MCF-
7 cells in vitro and in vivo. 
High IFIM1 expression is associated with increased blood vessel density and MMP1 
expression. 
Notably, we found that loss of IFITM1 significantly reduced angiogenesis in both 
the MIND and orthotopic models of breast cancer, as demonstrated by CD31 staining 
(Figure 3.9A and Figure 3.9B). This was seen in the doxycycline-treated MCF-7:5C/shIF 
groups in both the orthotopic and MIND models of breast cancer. Immunohistochemistry 
for CD31 expression demonstrated a significant decrease in blood vessel density in 
both models. Increased blood vessel density was also seen in MCF-7 tumors 
overexpressing IFITM1 as compared to control (Supplemental Figure 3.5).  
Since IFITM1 expression positively correlated with invasion we also measured 
matrix metalloproteinase 1 (MMP1) expression in our MIND xenografts. We found that 
MMP1 was upregulated in AI-resistant MCF-7:5C/shIF cells at the leading edge of 
invasion, while the non-invasive cells inside of the duct remain MMP1 negative (Figure 
3.9C, left panel). Notably, loss of IFITM1 (+Dox) reduced the number and extent of 
invasive lesions and was associated with lower MMP1 expression (Figure 3.9C, right 





MCF-7:5C/shIF xenografts from the orthotopic (a) and MIND model experiments were stained for 
CD31 expression using immunohistochemistry. Blood vessel density was determined by counting 
the number of CD31 positive blood vessels in at least 4 random 10X fields in each group from 
three separate samples. Graphs represent the average number of vessels per field. (c) 
Immunohistochemistry staining for matrix metalloproteinase 1 (MMP1) is shown. Mammary ducts 
are outlined in gray and MMP1 positive invasive cells indicated with arrows. ** p< 0.01 
Figure 3.9 Loss of IFITM1 reduces blood vessel density and MMP1 expression. 




Previous work in our lab demonstrated that AI-sensitive cell lines and patient 
tumors do not express IFITM1, while AI-resistant cells and tumors express IFITM1 at a 
high level.59  It is not known what drives AI-resistance, however, alterations in ER, 
growth factor, PI3K/Akt/mTOR, apoptosis and autophagy signaling have been identified 
as potential  mechanisms in both preclinical and clinical studies.27,29-31 Notably, when 
we overexpressed IFITM1 in MCF-7 cells (MCF-7/IF-1 and MCF-7/IF-2) we found that 
IFITM1 overexpression enhanced MCF-7 cell proliferation and tumorigenicity. It is 
significant that IFITM1 overexpression also improved breast cancer cell survival and 
aggression under estrogen-deprived conditions. IFITM1 expression is driven by type 1 
IFN mediated JAK/STAT signaling.2,66,72 Notably, enhanced STAT protein expression 
and activation have been linked to breast cancer development, progression and 
therapeutic resistance.54,67,69,126 IFITM1 overexpression is likely one of the ways that 
JAK/STAT signaling drives breast cancer development, aggression and therapeutic 
resistance. 
Using the orthotopic model we found that overexpressing IFITM1 increased 
tumor proliferation in the mammary fat pad and that loss of IFITM1 in AI-resistant cells 
reduced cell proliferation and induced death in vivo. The effect of IFITM1 expression on 
tumor proliferation and survival was likely due in part to the effect that IFITM1 had an 
effect on CD31+ blood vessel density in vivo. IFITM1 in endothelial cells is known to 
promote angiogenesis but the mechanism by which cancer cell IFITM1 expression 
drives angiogenesis warrants further study in our system.127 The MIND model was 
developed to study the progression of ductal carcinoma in situ (DCIS) to invasive breast 
cancer.123,124 While the orthotopic model is the most common method of studying breast 
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cancer in animals we used and validated the use of the MIND model as in vivo invasion 
assay. We discovered that IFITM1 expression can increase MCF-7 cell invasion while 
loss of IFITM1 can inhibit invasion out of the mammary duct. Recently, it has been 
shown that the MIND model can be used to study ER+ breast cancer invasion and 
metastasis and that the model maintains the phenotype of ER+ breast cancer cells 
more faithfully than the orthotopic model.125 Specifically, the MIND model maintains 
higher ERα expression than the orthotopic model, which has implications for in vivo 
investigations of ER+ breast cancer.128 We found that results from the MIND model also 
reflected the differences in MCF-7 and MCF-7:5C cells aggression. AI-resistant MCF-
7:5C MIND xenografts were significantly more invasive than AI-sensitive MCF-7 
xenografts. Notably, invasive lesions showed an induction in matrix metalloproteinase 1 
(MMP1) at the leading edge of invasion. IFITM1 is thought to promote invasion and 
inflammation through control of the expression of several matrix metalloproteinases 
(MMPs).129-131 The mechanism of IFITM1 control over MMP expression and activity 
remains unknown and warrants further study in our IFITM1-overexpression breast 




MATERIALS AND METHODS 
Cell lines and culture conditions  
The MCF-7 cell line 42,132 was obtained from Dr. V. Craig Jordan (University of Texas 
MD Anderson Cancer Center, Houston) and maintained in RPMI-1640 medium 
supplemented with 10% fetal bovine serum, 2 mM glutamine, Antibiotic/Antimitotic mix, 
MEM Non-Essential Amino Acids (Invitrogen, Waltham, MA), and bovine insulin at 6 
ng/mL (Sigma Aldrich, St. Louis, MO). The long-term estrogen deprived human breast 
cancer cell lines; MCF-7:5C and MCF-7:2A 122,132 were cloned from parental MCF-7 
cells following long term (> 12 months) culture in estrogen-free medium composed of 
phenol red-free RPMI-1640, 10% fetal bovine serum treated three times with dextran-
coated charcoal (SFS), 2 mM glutamine, bovine insulin at 6 ng/mL, Antibiotic/Antimitotic 
mix, and MEM Non-Essential Amino Acids (Invitrogen). The MCF10A cell line was 
purchased from the American Type Tissue Culture Collection. They are maintained in 
Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12) in a 1:1 mixture 
and supplemented with 5% horse serum, Antibiotic/Antimitotic mix (100 IU/mL penicillin, 
100 μg/mL streptomycin, 25 µg/mL of Fungizone® from Invitrogen, Grand Island, NY), 
20ng/ml EGF (Millipore), 0.5mg/ml hydrocortisone, 100ng/ml cholera toxin (Sigma 
Aldrich). All cell lines were cultured at 37°C under 5% CO2.  
Western blotting  
Cells were seeded in 6-well plates, collected using a cell scraper and suspended in 
RIPA buffer (Thermo Scientific, Pittsburgh, PA) supplemented with protease inhibitor 
cocktail and phosphatase inhibitor (Sigma Aldrich). Cells were homogenized over ice by 
sonication. After purification of the sample by centrifugation, protein concentration was 
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determined by protein assay (Bio-Rad, Hercules, CA). The proteins were separated by 
4-12% SDS–polyacrylamide gel electrophoresis (SDS–PAGE) and electrically 
transferred to a polyvinylidene difluoride membrane (Santa Cruz Biotechnology). After 
blocking the membrane using 5% non-fat milk, target proteins were detected using anti-
IFITM1, anti-PARP, anti-ERα, anti-phospho-STAT1 (ser701), anti-STAT1, anti-p21, anti-
p53 or anti-laminin B (Santa Cruz Biotechnology) antibodies. Membranes were stripped 
and re-probed for β-actin (Cell Signaling). The appropriate horseradish peroxidase 
(HRP)-conjugated secondary antibody was applied and the positive bands were 
detected using Amersham ECL Plus Western blotting detection reagents (GE Health 
care, Piscataway, NJ) and exposed to autoradiography film (Midwest Scientific). 
RNA isolation and RT-PCR analysis  
Total RNA was isolated from cultured cells using the RNeasy® Mini Kit(Qiagen, Venlo, 
Netherlands) according to the manufacturer′s procedure. First strand cDNA synthesis 
was performed from 2.5 µg total RNA using Super- Script Reverse Transcriptase 
(Invitrogen). cDNA was amplified in a 15-µl PCR mixture containing 1 mm dNTPs, 1× 
PCR buffer, 2.5 mm MgCl2, and 1 U DNA Taq polymerase (Promega, Madison, WI) 
with 25 pmol of primers specific for human PLSCR1 (sense: 5′-
CATTCACCGGGCTCTCTAC-3′; antisense: 5′-GGCAGCTGGGCA ATCTTGCA-3′), 
IFITM1 (sense: 5′-GGATTTCGGCTTGTCCCGAG-3′; antisense: 5′- CCATG 
TGGAAGGGAGGGCTC-3′), IRF9 (sense: 5’-TTCTGTCCCTGGTGTAGAGCCT-3’, 
antisense: 5’- TTTCAGGACACGATTATCACGG-3’), IRF7 sense: 5’-
GAGCCCTTACCTCCC CTGTTAT-3’, antisense: 5’-CCACTGCAGCCCCTCATAG-3’, 
IFI27 (sense: 5’- GCCTCTGG CTCTGCCGTAGTT-3’, antisense: 5’-
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ATGGAGGACGAGGCGATTCC-3’), IFIT1 (sense 5’-TCTCAGAGGAGCCTGGCTAA-3’, 
antisense 5’-CCAGACTATCCTTGACCTGATGA-3’), MX1 (sense: 5’-
CTTTCCAGTCCAGCTCGGCA-3’, antisense: 5’-AGCTGCTGGCCGTACGT CTG-3’), 
OAS1 sense: 5’-TGAGGTCCAGGCTCCACGCT-3’, antisense: 5’-GCAGGTC 
GGTGCACTCCTCG-3’), STAT1 (sense: 5’-GGCACCAGAACGAATGAGGG-3’, 
antisense: 5’-CCATCGTGCACATGGTGGAG-3’, STAT2 (sense: 5’-
GCAGCACAATTTGCGGAA-3’, antisense: 5’-ACAGGTGTTTCGAGAACTGGC-3’).  The 
condition in the logarithmic phase of PCR amplification was as follows: 5 min initial 
denaturation at 94°C, 1 min denaturation at 94°C, 35 sec annealing at 67°C, and 1.5 
min extension at 72°C for 30 cycles. The number of amplification cycles during which 
PCR product formation was limited by template concentration was determined in pilot 
experiments. PUM1 was used as the internal control (sense: 5′-
TCACCGAGGCCCCTCTGAACCCTA-3′; antisense: 5′-
GGCAGTAATCTCCTTCTGCATCC T-3′). The reproducibility of the quantitative 
measurements was evaluated by three independent cDNA syntheses and PCR 
amplification from each preparation of RNA. Densitometric analysis was performed 
using Scion Image software (Scion Corp, Frederick, MD), and the relative mRNA 
expression level was determined as the ratio of the signal intensity of the target to that 
of PUM1. 
TUNEL Staining 
TUNEL staining was conducted using the Invitrogen Click-iT™ Plus TUNEL assay kit on 
either methanol fixed cell lines grown on chamber slides or deparaffinized tissue (See 
below) following manufacturer’s instructions (Thermo Fisher Scientific). The average 
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TUNEL intensity was quantified using the red color channel on Image J software from a 
minimum of three images. 
Plasmid DNA construction 
shRNA cloning was performed utilizing Gateway® Technology (Invitrogen Life 
Technologies). Double stranded IFITM1 shRNA was generated as previously 
described.133 The vectors used for cloning were a kind gift from Eric Campeau. Briefly, 
double stranded IFITM1 shRNA (5’-
GATCGCTGTGACAGTCTACCATATTTCAAGAGAATATGGTAGACTGTCACAG-3’) 
and scrambled shRNA sequences (5’-CATCGCCTAAGGTTAAGTCGCCCTCGCTCG 
AGCGAGGGCGACTTAACCTTAGG-3’,) were inserted into the pENTR/pTER+ vector 
(430-1) (Addgene #17453), placing their expression under the control of the inducible 
H1/TO promoter which contains a Tet-operator (TetO). The pENTR/pTER+ shRNA 
constructs were then incubated with LR clonase II enzyme mix (Invitrogen) and 
pLentiX2-Hygro-DEST (w17-1) (Addgene #17295) vector to generate pLentiX2 
DEST/shIFITM1 and pLentiX2 DEST/shCon constructs.  
Virus preparation and transduction 
Lentivirus preparation was performed as previously described.133 Briefly, pLentiX2 
DEST constructs were co-transfected with pVSVG packaging vectors into HEK293T 
cells using Lipofectamine 2000 (Invitrogen). Medium was changed after 24 hours and 
viral supernatant was harvested 48 hours later. Virus-containing medium was then 
filtered using a 0.45μM syringe filter (Millipore). MCF-7:5C cells were then seeded in 6-
well plates and allowed to reach 70% confluence overnight. 400 μL of viral supernatant 
of the filtered supernatant and 1mL 
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Lentivirus expressing pLenti CMV rtTA3 BLAST (TetR) vector (w756-1) was another 
kind gift from Eric Campeau purchased from Addgene.133 First, transduction of MCF-
7:5C cells with the construct was accomplished using 100 µL virus-containing medium 
in 2 mL normal medium and 3 µg/mL polybrene which generated MCF-7:5C/TetR cells 
which express the TetR gene under a CMV promoter. TetR expression occupies TetO 
sites, keeping target-genes silenced until tetracycline or doxycycline exposure. MCF-
7:5C/TetR cells were then transduced with the pLentiX2 DEST constructs which 
produced the MCF-7:5C/TetR/shCon (MCF-7:5C/shCon) and MCF-7:5C/TetR/shIFITM1 
(MCF-7:5C/shIF) cell lines. 
CRISPR /Cas9 Lentiviral Activation of IFITM1 
IFITM1 Lentiviral Activation Particles (Santa Cruz sc-416878-LAC) is a synergistic 
activation mediator (SAM) transcription activation system designed to specifically and 
efficiently upregulate gene expression via lentiviral transduction of cells. IFITM1 
Lentiviral Activation Particles (h) contain the following SAM Activation elements: a 
deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation 
domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt. guide RNA. 
Upon transduction, the SAM complex binds to a site-specific region approximately 200-
250 nt. upstream of the transcriptional start site and provides robust recruitment of 
transcription factors for highly efficient gene activation. Viral transduction and cloning 




Cells were assayed for viability in 24-well plates in triplicate in either estrogen or 
estrogen-free medium (see Cell Culture Conditions). At each time point, a measure of 
the viable cells was taken using the Cell-Titer Blue Assay Kit (Promega, Madison, WI) 
per the manufacturer’s instructions. Assay plates were kept at 37˚C in 5% CO2 for 3 
hours and read at 560-590 nM on a BioTek Synergy 4 microplate reader using the Gen 
5 data analysis software (BioTek Instruments, Winooski, VT). 
Soft Agar Anchorage-independent Growth Assay 
6-well plates were coated with 1 mL of 0.8% agarose in the appropriate culture media. 
Cells were then suspended in 0.48% agarose and immediately overlaid on the pre-
coated plates.  Once the agarose was solid, 1mL of culture medium with or without 
estrogen (see Cell Culture Conditions) and every 4 days for 20 days. Cultures were 
then stained with 50 μl of MTT solution (5 mg/mL) was added to each well at a final 
concentration of 500 μg/mL, and the plates were further incubated for 2 h at 37oC. 
Plates were imaged at 1X in a Bio-Rad ChemiDoc™ XRS+ System with Image Lab™ 
Software (Bio-Rad). Colonies were counted and measured using Image J software 
(NIH).  
Wound healing assay 
Cell lines were seeded in 6-well culture plates so that they would reach 70% confluence 
overnight. The next day, a single wound was made on the plates for each cell line by 
scratching the attached cells using a 200 μl sterile pipette tip. The plates were washed 
with complete medium to remove cellular debris from the scraped surface. The images 
of the cells were taken at 10X immediately, and after 24 and 48 hours using phase-
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contrast microscope. The area of the wound was quantified using the MRI Wound 
Healing Tool in Image J Software (NIH). 
Animals 
Recipients were 8- to 10-week-old virgin female NOD-SCID IL2Rgammanull (NSG) mice 
which were purchased from Jackson Laboratories or bred (a gift from Thomas Yankee, 
PhD at The University of Kansas Medical Center). Animal experiments were conducted 
following protocols approved by the University of Kansas School of Medicine Animal 
Care and Use. 
Orthotopic Cell Line Transplantation  
Cells were suspended in 50:50 PBS/Matrigel (Corning) were bilaterally into 4th 
mammary fat pads of NSG mice, as described previously. 48 3 x 106 cells were delivered 
per injection in a volume of 100μL. The length (L) and width (W) of tumors was 
measured weekly with digital calipers, and the tumor volume was calculated by the 
formula L2/(2W). When tumors reached a mean volume of 0.20 cm3, groups of 5-15 
mice were randomly assigned to treatment groups. For doxycycline treatment, mice 
were provided with 50 μg/mL doxycycline in dark water bottles to induce IFITM1 shRNA 
expression. Water was replaced weekly to maintain efficacy. Where indicated, mice 
were given 50 μg/kg body weight of Ruxolitinib suspended in methylcellulose by oral 
gavage every other day. When using MCF-7 cells, capsules made of medical grade 
silastic tubing (Dow-Corning) containing 1:4 estradiol/cholesterol (Sigma Aldrich) were 
implanted subcutaneously in the mice where indicated. These capsules produce a 
mean serum estradiol level of ~80 pg/mL, which is similar to postmenopausal serum 




Mammary intraductal transplantation (MIND) method 
MIND injections were conducted as previously described using 8-10 weeks old 
ovariectomized NSG mice. 123,134 Briefly, cells were resuspended as single cells in PBS 
and counted. A 30-gauge Hamilton syringe, 50-μl capacity, with a blunt-ended 1/2-inch 
needle was used to deliver the cells. The mice were anesthetized by ketamine/xylene 
injection, and a Y-incision was made on the abdomen, allowing exposure of the inguinal 
mammary fat pads. The nipple of the inguinal gland is snipped so that the needle can 
be directly inserted through the nipple. Two microliters of cell-culture medium (with 0.1% 
trypan blue) containing cells at a concentration of 2,500 to 5,000 cells/μl were injected. 
Successfully injection was confirmed by visual detection of trypan blue in the ductal tree 
branches. The skin flaps were then repositioned normally and held together with wound 
clips. When required, mice were provided with 50 μg/mL doxycycline in dark water 
bottles to induce IFITM1 shRNA expression. Water was replaced weekly to maintain 
efficacy. 
Tissue Harvesting and Preparation 
Mammary glands and solid tumors were removed and fixed in 4% paraformaldehyde for 
72 hours and then 70% ethanol. Fixed glands were then processed, embedded and 
sectioned by the Biospecimen Repository at the University of Kansas Medical Center. 
For immunohistochemical staining procedure see above. 
Immunofluorescent (IF) staining of tissue 
62 
 
IF was performed as previously described 124 after tissue deparaffinization by clearance 
in xylene and hydration through graded ethanol series. Antigen retrieval was conducted 
at 99˚C in Dako Target retrieval solution (S1700) for 20 min per manufacturer’s 
instructions (Agilent Technologies, Copenhagen, Denmark). Washes were performed in 
IF buffer (130 mM NaCl, 7 mM Na2HPO4, 3.5 mM NaH2PO4, 7.7 mM NaN3, 0.1% 
bovine albumin, 0.2% Triton X-100, 0.5% Tween-20). Due to use of mouse antibodies 
on mouse tissue, blocking and antibody dilution were performed using the Mouse on 
Mouse (MOM™) Kit following manufacturer’s instructions (Vector Labs, Burlingame, 
CA). Sections were stained using human antibodies targeted against Keratin 19 
(Neomarkers #MS-198-P1), anti- actin smooth muscle (Spring Biosciences #E2464), 
anti-ki67 (Dako #M7240), or anti-IFITM1 (Santa Cruz Technology). Secondary 
antibodies were FITC or Texas Red conjugated (Santa Cruz). Sections were mounted 
using ProLong® Gold Antifade Reagent with DAPI (Cell Signaling) and visualized on a 
Leica TCS SPE confocal microscope in the Confocal Imaging Core at The University of 
Kansas Medical Center. Images were collected and analyzed using the Leica LAS AF 
Lite software (Leica Biosystems, Nussloch, Germany). For quantification, mean 






Supplemental Figure 3.1 Doxycycline induced IFITM1 shRNA expression is specific to 
MCF-7:5C/IFsh cells. 
 (a) 3 million MCF-7:5C/Con cells were injected in an accompanying experiment. Tumors were 
measured by digital calipers and tumor volume (mm3) displayed over time (left panel). Excised tumor 
weight (mg) and volume (mm³) was measured (right panel). (b) Excised tumors were fixed, embedded 
in paraffin and sectioned onto glass slides. IFITM1 and Ki67 expression was determined by 
immunohistochemical staining. The percent of Ki67 positive cells was determined by counting four 
separate 40X fields. Cell death was analyzed by TUNEL staining and quantified by Image J software 










5,000  (a-d) MCF-7:5C/C9Con cells were injected into the duct of the 4th mammary gland of female 
ovarectomized NSG mice by the MIND injection protocol. After 10 days, mice were randomized to 
treatment groups and half were provided doxycycline (Dox)-treated drinking water. After 3 weeks, 
mammary glands were removed and processed. Immunofluorescent staining of the breast cancer cells 
for (b) human keratin 19 (HuK19-red), or (c) IFITM1 and the mammary duct for smooth muscle actin 
(SMA-green) was conducted. As well as (d) Ki67, TUNEL (quantified on the right) and (e) p21 staining 
(quantified in lower panel) 
 
Supplemental Figure 3.2 MIND injection of MCF-7:5C/IFsh and MCF-7:5C/C9Con cells. 
Lui et al. Cancer Letters. 2017 Apr 12;399:29-43 
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 (a) 5,000 MCF-7 or MCF-7:5C cells were injected into the duct of the 4th mammary gland of female 
NSG mice use the MIND injection protocol. After 4 weeks, mammary glands were removed. Mammary 
glands were fixed and processed onto glass slides. ERα expression was determined by 
immunohistochemistry. (b) 3 million MCF-7 or MCF-7:5C cells were injected into the 4th mammary fat 
pad of female NSG mice. After 43 days, tumors were excised, fixed, embedded in paraffin and 
sectioned onto glass slides. ERα expression was determined by immunohistochemistry.  
 
Supplemental Figure 3.3 Expression of ERα is higher in MIND verses orthotopic 
mouse tumors. 




 (a) The proliferation of parental MCF-7, MCF-7/C9Con and MCF-7/IF-1 was measured over 96 hours 
by Cell Viability assay. (b) MCF-7/C9Con and MCF-7/IF-1 cells were subjected to soft agar anchorage 
independent growth assay. After 21 days the number of colonies was quantified using Image J (right 
panel). Values represent two independent experiments conducted in duplicate. (c) Scratch assay was 
conducted on 70 % confluent plates of MCF-7/C9Con and MCF-7/IF-1 cells. Plates were imaged at 0, 
24 and 48 hours and the size of the wound was quantified by image J (right panel). Values represent 
two independent experiments conducted in triplicate. (d) Intact female NSG mice were orthotopically 
injected with MCF-7/C9Con and MCF-7/IF-1 cells. Tumor volume (mm3) was calculated and charted 
over time.  (e) Tumors were imaged and final tumor volume (mm3) determined. (f) IFITM1 and Ki67 
expression was determined by immunohistochemical staining. The percent of Ki67 positive cells was 
determined by counting four separate 40X fields (left panel).  
  
Supplemental Figure 3.4 Overexpression of IFITM1 promoted breast cancer cell 
proliferation and invasion. 




(a) MCF-7:5C/shCon cells were injected into the 4th mammary gland of ovarectomized female  NSG 
mice using either the MIN or orthotopic model. (b) 3 million MCF-7/C9Con, MCF-7/IF-1, MCF-7/IF-2  
cells were injected into the 4th mammary fat pad of female NSG mice. Immunohistochemical staining 
for CD31 visualized the blood vessels in each tumor. The number CD31 positive blood vessels was 
quantified using at least 4 random 10x fields in each group. 
 
Supplemental Figure 3.5 IFITM1 expression is associated with angiogenesis. 
Lui et al. Cancer Letters. 2017 Apr 12;399:29-43 
68 
 
CHAPTER 4 : ROLE OF IFITM1 IN CONTROLLING CELL CYCLING AND SURVIVAL 
 
This chapter is adapted from: 
 
Lui A, Ogony J, Geanes E, Behbod F, Valdez K, Marquess J, Jewell W, Tawfik O, 
Lewis-Wambi J. IFITM1 suppression blocks proliferation and invasion of aromatase 
inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21. Cancer 
Lett. 2017 Apr 12;399:29-43. 
 
INTRODUCTION 
IFITM1 is a transmembrane interferon stimulated gene (ISG) that is normally induced in 
response to IFN exposure to aid in resistance to viral infections. In addition to inhibiting 
viral entry and replication, ISGs are also known to modulate the decision between cell 
survival and death.54,66,72,76 In fact, one study has found that the expression of ISGs 
increases in mouse models of endocrine resistance.88 IFITM1 specifically is thought to 
promote the survival of epithelial cells and to allow cancer cells to survive chemotherapy 
and radiation.54,76 These therapies function mainly by inducing DNA damage which 
initiates cell cycle arrest and cell death.  
p21 
The cell cycle is tightly controlled by a variety of proteins and signaling cascades. Cell 
cycle progression is driven by cyclin dependent kinases (CDKs) which phosphorylate 
target proteins such as the retinoblastoma susceptibility protein (Rb). CDKs are 
activated by interaction with cyclin proteins (Cyclin A, B , D and E) and are regulated by 
the CDK inhibitors of the INK and Cip/Kip families.135,136 The CDK inhibitor p21 
(p21w af1/cip1) is the most prominent member of the Cip/Kip family and is known to arrest 
the cell cycle at the G1/S and G2/M checkpoints through inhibition of CDK and cyclin 
protein complex activity. The most well-known activator of p21 is p53, which is a 
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transcription factor that drives p21 expression in response to DNA damage (ie 
chemotherapy and radiation).137,138 p21 is a potent driver of cell cycle arrest and so is 
often silenced in cancer due to its role as a tumor suppressor. Conversely, p21 is also 
frequently overexpressed in the cytoplasm of cancer cells and is associated with poor 
prognosis because cytoplasmic p21 can inhibit apoptosis through prevention of caspase 
activation, repression of E2F-1 activity and inhibitory interactions with pro-apoptotic 
proteins in the cytoplasm like apoptosis signal regulating kinase 1 (ASK1) (Figure 
Depending on intracellular localization, p21Waf1 is implicated in regulation of the cell cycle, DNA 
repair, apoptosis, and reorganization of the actin cytoskeleton. For example, in the nucleus the 
Cterminus of p21Waf1 interacts with a DNApolymerase δ subunit, PCNA, and thereby inhibits  DNA 
replication. p21Waf1 can directly interact with PARP1 enzyme, a marker of both single and 
doublestranded DNA breaks that plays an important role in DNA repair via interacting with many repair 
proteins. Beside the traditional role of cytoplasmic p21Waf1  in regulating cyclin CDK2 complex 
inactivation, the cytoplasmic p21Waf1 can also bind to and regulate the Rhoassociated kinase 1 
(ROCK1) cascade. This cascade is required for actin stress fiber and focal contact formation, which 
allows for cancer cell migration. Additionally cytoplasmic p21Waf1 can inhibit apoptosis by blocking 
procaspase-3 cleavage and apoptosis signal-regulating kinase 1 (ASK1).  7 
Figure 4.1 Nuclear and cytoplasmic functions of p21waf1 
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4.1).139,140 When p21 is in the cytoplasm it is no longer a negative regulator of the cell 
cycle. Instead, cytoplasmic p21 can be stabilized by phosphorylation in response to pro-
survival signals like PI3K/Akt and Ras signaling and there is growing evidence that 
cytoplasmic p21 is oncogenic, protecting many cancers from DNA damage-induced 
apoptosis. 7 Interestingly, cytoplasmic p21 is also thought to control reorganization of 
the actin cytoskeleton through interaction with Rho-associated kinase 1 (ROCK1) which 
also gives p21 a role in cell migration.7,138 The cellular localization of p21 is important in 
determining the role that it plays in cancer. 




Loss of IFITM1 induces p21 expression in AI-resistant cells.  
We previously demonstrated in chapter 3 that IFITM1 knockdown induced cell 
death of AI-resistant MCF-7:5C cells. It is known that IFN signaling and ISGs modulate 
cell cycle progression and cell survival, so we assessed the mechanism by which 
IFITM1 loss induces cell death in AI-resistant MCF-7:5C cells. Our mechanistic studies 
focused on p21 and p53 which are important regulators of cell cycle progression and 
cell death.  We found that siRNA knockdown of IFITM1 in the MCF-7:5C cells induced 
p21, while having no effect on p53 (Figure 4.2A) and this effect was true for all three 
siRNA constructs as well as the inducible IFITM1 shRNA system (Figure 4.2B). The 
induction of p21 was associated with cell cycle arrest (Figure 4.2C). Notably, 
doxycycline-induced loss of IFITM1 significantly reduced the percentage of MCF-
7:5C/shIF cells that were in G0/G1 phase (Figure 4.2C); however, doxycycline exposure 
did not affect the cycling of wild type MCF-7:5C or MCF-7:5C/shCon cells. Concurrent 
knockdown of IFITM1 and p21 demonstrated that p21 was necessary for the induction 
of cell death using either the siRNA (Figure 4.2D) or shRNA approaches (data not 
shown). We should note that IFITM1 knockdown not only increased p21 expression but 
also increased STAT1 phosphorylation which was blocked by concurrent p21 
knockdown (Figure 4.2E). Concurrent knockdown of IFITM1 and p53 had no effect on 
cell death or STAT1 activation (data not shown). 
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(a) Cell lysates from MCF-7:5C cells transfected with scrambles control siRNA (siCon) or three 
different IFITM1 siRNA sequences (siIFITM1 A, B, C) were immunoblotted for IFITM1, p53 and p21 
expression. (b) MCF-7:5C cells were transiently transfected with siCon or siIFITM1C while MCF-
7:5C/shIF cells were treated with vehicle or 1μM doxycycline (Dox). Cells were harvested after 48 and 
72 hours respectively and then lysates were immunoblotted for IFITM1 and p21 expression. (c) MCF-
7:5C, MCF-7:5C/shCon and MCF-7:5C/shIF cells were treated with vehicle or control over 72 hours. 
Samples were harvested and fixed at 24, 48 and 72 hours for cell cycle analysis. The percent of cells 
in G0/G1 phase is displayed and represents means from two experiments conducted in duplicate ± 
standard deviation.  MCF-7:5C cells were transfected with siCon, siIFITM1C, p21 siRNA (siP21) or 
siIFITM1-C with sip21. (d) Dual Annexin V/Propidium Iodide staining was used to quantify cell death in 
each transfection group as compared to siCon. Data represent means ± SD from two experiments 
conducted in duplicate (right panel). (e) Whole cell lysates were immunoblotted for p-STAT1, STAT1, 
IFITM1 and p21 expression. ** p<0.01 
 
Figure 4.2 Loss of IFITM1 expression was associated with increased p21 expression, 
which mediated cell death. 
Lui et al. Cancer Letters. 2017 Apr 12;399:29-43 
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IFITM1 knockdown increased p21 expression through enhanced STAT1 activity.  
The p21 promoter is known to have binding motifs for a variety of transcription 
factors including p53, SP1, AP2 and STAT1.135,137 Since IFITM1 knockdown induced 
STAT1 phosphorylation we investigated whether loss of IFITM1 had an effect on p21 
transcription. Using a p21 promoter luciferase reporter, we found that STAT1 but not 
STAT2 activated p21 transcription in MCF-7:5C cells and that loss of IFITM1 expression 
significantly increased p21 promoter activity (Figure 4.3A). To test whether the 
enhanced transcriptional activity at the p21 promoter was mediated by STAT1 we used 
a STAT1 motif luciferase reporter. We found enhanced basal STAT1 transcriptional 
activity in the MCF-7:5C cells which was completely abrogated by inhibiting STAT1 
phosphorylation with the JAK1/2 inhibitor ruxolitinib (Rux). Significantly, IFITM1 
knockdown doubled STAT1 transcriptional activity in AI-resistant MCF-7:5C cells 
(Figure 4.3B).  
To demonstrate that the increase in p21 transcription was indeed mediated by STAT1 
activation, we knocked down IFITM1 in the presence and absence of Rux. Inhibition of 
STAT1 phosphorylation (activation) prevented the increase in p21 expression normally 
seen when IFITM1 is lost (Figure 4.3C). The direct effect on p21 transcription was 
demonstrated using the p21 promoter luciferase reporter using both IFITM1 siRNA 
(Figure 4.3D) and inducible shRNA (data not shown). The importance of JAK/STAT 
signaling during IFITM1 knockdown-induced cell death was further elucidated by cell 
viability and annexin V/PI staining. Rux treatment significantly blunted the negative 
effects of IFITM1 loss on cell survival (Figure 4.3F). 
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(a) Activity at the p21 promoter was determined by luciferase assay. MCF-7:5C cells were transfected 
with p21 luciferase reporter and renilla reporter constructs with scrambled control (siCon) or IFITM1C 
siRNA (siIFITM1). (b) STAT1 transcriptional activity was determined by gamma associated sequence 
(GAS) luciferase assay cocktail. MCF-7:5C cells were transfected with GAS luciferase cocktail and 
with siCon or siIFITM1 or treated with 10μM ruxolitinib (Rux). (c)  MCF-7:5C cells transfected with 
either siCon or siIFITM1 were also treated with 10μM Rux or vehicle. Whole cell lysates after 24 and 
48 hours of treatment were immunoblotted for phospho-STAT1 (p-STAT1), STAT1, IFITM1 and p21 
expression. (d) p21 luciferase assay determined relative activity at the p21promoter when MCF-7:5C 
cells were transfected with siCon or three IFITM1 siRNA sequences (siIFITM1A, B, C). After overnight 
transfection, cells were then treated with 10μM Rux or vehicle (Con) and assayed after 24 hours of 
Rux treatment. (e) The percent of viable cells after siCon or siIFITM1-C (siIFITM1) transfection with 
and without 10μM Rux was determined by cell titer blue cell viability assay after 24, 48 and 72 hours of 
treatment. Values are means ± SD of two independent experiments conducted in triplicate. (f) MCF-
7:5C cells were transfected with siCon or siIFITM1C, treated with 10μM Rux or transfected with 
siIFITM1C and treated10μM Rux in combination. Dual annexin/PI staining was used to quantify cell 
death in each transfection group as compared to untreated siCon. *p < 0.05, ** p< 0.01 
 
Figure 4.3 IFITM1 knockdown increases p21 expression via enhanced STAT1 activity. 
Lui et al. Cancer Letters. 2017 Apr 12;399:29-43 
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Loss of IFITM1 is associated with nuclear translocation of p21.  
The cellular localization of p21 also plays a role in cell survival. To investigate 
whether localization of p21 is altered in MCF-7:5C cells we fractionated the cytoplasmic 
and nuclear fractions of AI-sensitive parental MCF-7 cells and AI-resistant MCF-7:5C 
cells and found significantly diminished p21 expression in the nuclear fraction of MCF-
7:5C cells. Low nuclear to cytoplasmic ratio of p21 is associated with cancer aggression 
and resistance to therapy (Figure 4.4A). We then used our MCF-7:5C/shIF cells to 
determine the effect of IFITM1 loss on p21 localization. Both cell lysate fractionation and 
immunofluorescent staining revealed that loss of IFITM1 is associated with increased 
nuclear translocation of p21 (Figure 4.4B and Figure 4.4C). Interestingly, treatment with 
Rux prevented not only enhanced p21 expression, but also prevented induced nuclear 
translocation (Figure 4.4B and Figure 4.4C). Our data suggest that IFITM1 expression is 
inversely related to p21 nuclear localization and that p21 nuclear translocation may be a 




Figure 4.4 Loss of IFITM1 induces p21 nuclear translocation. 
(a) Fresh whole cell lysates from 80% confluent MCF-7, and MCF-7:5C were separated into nuclear 
(laminin B) and cytoplasmic (β-actin) fractions. Protein expression of p21 and IFITM1 was determined 
by immunoblotting. (b) MCF-7:5C/shIF cells with and without doxycycline (± Dox) exposure were also 
treated with 10μM ruxolitinib (Rux). After 48 hours Rux treatment, cells were harvested and fresh 
whole cell lysates were fractionated and immunoblotted for p21, phospho-STAT1 (p-STAT1), STAT1 
and IFITM1 protein expression. (c) MCF-7:5C/shIF cells with and without doxycycline (± Dox) 
exposure were also treated with 10μM ruxolitinib (Rux). After 48 hours Rux treatment, p21 and 
IFITM1expression and localization as determined by immunofluorescent staining.  
 
 




We generated an inducible model of IFITM1 loss in MCF-7:5C cells and found 
that IFITM1 expression was critical to the survival of AI-resistant cells. In particular, we 
discovered that IFITM1 overexpression was required to maintain the survival and 
aggressive phenotype of AI-resistant MCF-7:5C cells whereas loss of IFITM1 induced 
cell cycle arrest and apoptosis. Mechanistic studies revealed that loss of IFITM1 
markedly induced p21 expression which was dependent on STAT1 activation but not 
p53. While p53 is a well-known transcriptional regulator of p21, several other 
transcription factors also activate p21 expression in a p53-independent manner.139 
Indeed, DNA-binding elements for several transcription factors are present in the 
proximal p21 promoter, including three STAT1 binding sites.139 These responsive 
elements are utilized to regulate p21 expression in response to various stimuli and 
stress signals. We have previously reported that total STAT1 and p(Y701)-STAT1 are 
significantly elevated in AI-resistant MCF-7:5C cells and that constitutive activation of 
the JAK/STAT pathway plays a critical role in driving IFITM1 overexpression in these 
cells.59 In the present study, increased p21 expression was associated with cell cycle 
arrest and cell death, which is consistent with similar studies in other cancer models 
(Figure 4.5).139 High expression of cytoplasmic p21 is known to promote cell survival 
and cell cycling while higher nuclear p21 stimulates cell death.135,141,142 Cancers with 
high p21 cytoplasmic/nuclear ratio are thought to be more aggressive, hence our finding 
that AI-resistant MCF-7:5C cells have very high expression of IFITM1 but very low 
nuclear p21 expression is consistent with their highly aggressive phenotype both in vitro 
and in vivo.140,143,144 Notably, loss of IFITM1 drove p21 nuclear translocation which can 
be induced by p21 threonin-145 phosphorylation by Akt1 and murine leukemia virus 
78 
 
(Pim-1).135,136 Pim-1 is known to promote tumor aggression and high Pim-1 expression 
is associated with poor prognosis in various cancers.145-147 Specifically Pim-1 is thought 
to promote inflammation induced tumorigenesis, and promote cancer cell survival of 
chemotherapy and radiation treatment.148-151 In breast cancer, high Pim-1 expression is 
associated with PI3K/Akt mediated drug resistance.152 The PI3K/Akt pathway has long 
been associated with endocrine resistance in ER+ breast cancer.153-157 In fact, we have 
investigated the efficacy of FDA approved mTOR inhibitor everolimus/Afinitor™ in 
targeting AI-resistant breast cancer (Appendix A).  Interestingly, Pim-1 expression itself 
is mediated by JAK/STAT signaling and stress signals including cytokine exposure and 
viral infection in a similar manner to IFITM1.158,159 Significantly, in this study, 
overexpression of IFITM1 promoted MCF-7 cell survival in estrogen-deprived 
conditions. Whether IFITM1 modulates Akt1 and Pim-1 activity and p21 phosphorylation 
requires further study.  
Lui et al. Cancer Letters. 2017 Apr 12;399:29-43 
Figure 4.5 Loss of p21 drives cell death through regulation of p21 expression and 
cellular localization. 
Loss of IFITM1 expression drives JAK/STAT mediated increases in p21 transcription and nuclear 
translocation. This change in p21 expression and localization drives cell death and can be blocked 




MATERIALS AND METHODS 
RNA Isolation and Real Time PCR 
Cells were harvested by cell scraping in RLT lysis buffer and total RNA was isolated 
using the Qiagen RNeasy kit (Venlo, Limburg). First strand cDNA synthesis was 
performed from 3 μg total RNA using MulV Reverse Transcriptase (Applied Biosystems, 
Carlsbad, CA) on a Bio Rad MyCycler™. RT-PCR was conducted using the ViiA™ 7 
Real-Time PCR system (Applied Biosystems) and SYBR Green Reagent (Life 
Technologies, Carlsbad, CA) with 25 pmol primers specific for human PLSCR1 (sense: 
5′-CATTCACCGGGCTCTCTAC-3′; antisense: 5′-GGCAGCTGGGCA ATCTTGCA-3′), 
IFITM1 (sense: 5′-GGATTTCGGCTTGTCCCGAG-3′; antisense: 5′- 
CCATGTGGAAGGGAGGGCTC-3′). Relative mRNA expression level was determined 
as the ratio of the signal intensity to that of PUM1 using the formula: 2-ΔCT. When cells 
were treated, fold change in ERα expression was normalized to PUM1 and then 
compared to the untreated value for that cell line using the formula: 2-ΔΔCT.  
Small interfering RNA (siRNA) transfections  
Cells were transiently transfected with siRNA for IFITM1 (cat# sc-44549A/B/C), p21, 
MUC1 or a scrambled negative control (cat# sc-37007) (Santa Cruz Biotechnology, 
Santa Cruz, CA). All of the siRNAs were pools of three target specific 20 to 25 nt 
siRNAs. Cells were seeded the night before transfection and allowed to reach 60% 
confluence by the time of transfection. Twenty nmol of each siRNA was introduced 
using Lipofectamine 2000 in OptiMEM Reduced-Serum Medium (Invitrogen, San Diego, 
CA, USA) according to the manufacturer’s instructions. After overnight incubation, the 
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transfection mixture was replaced with normal culture medium containing 1 μg/mL 
doxycycline, only where indicated. 
Annexin V Apoptosis Assay 
The annexin V–FITC-labeled Apoptosis Detection Kit I (BD Pharmingen, San Diego, 
CA) was used to detect and quantify apoptotic cells by flow cytometry according to the 
manufacturer′s instructions. In brief, cells were seeded in 6-well plates and cultured for 
up to 118 hours in their regular media or with 1 μg/mL doxycycline, where indicated. 
Media was changed at 72 hours for longer experiments. Cells were then harvested by 
trypsinization and resuspended in 1 × binding buffer (HEPES buffer, 10 mM, pH 7.4, 
150 mM NaCl, 5 mM KCl, 1 mM MgCl2, and 1.8 mM CaCl2). Samples were stained 
simultaneously with FITC-labeled annexin V (25 ng/mL) and propidium iodide (PI) (50 
ng/mL). Cells were analyzed using the BD FACSAria™ II Flow Cytometer (BD, Franklin 
Lakes, NJ) in the Flow Cytometry Core Facility at the University of Kansas Medical 
Center, and the data was analyzed with FlowJo software (Ashland, OR). 
Cell Cycle Analysis 
Cells were incubated in the appropriate cell culture media with and without doxycycline 
treatment. Cells were harvested at the indicated time points by trypsinization and then 
fixed with 0.9% NaCl and ice cold ethanol. Once all samples were collected, DNA was 
stained with 50 µg/mL Propidium Iodide and 100 µg/mL RNase A in PBS (Invitrogen).  
Samples were analyzed using a BD FACSAria™ II Flow Cytometer in the flow 
cytometry core at The University of Kansas Medical Center (BD, Franklin Lakes, NJ). 




For IFITM1 and p21 promoter assays, 0.8 μg of plasmid DNA and the pRL CMV Renilla 
vector were used as previously described.73 For analysis of IFITM1 promoter activity, 
the pGL3 plasmid with the first 750 nucleotides of the IFITM1 promoter inserted (pGL3-
IFITM1 [−750/-1]), was used.73 The pGL3-Basic-IRES was a kind gift from Joshua 
Mendell (Addgene #64784).160  For analysis of p21 promoter activity, the pGL2-p21 
promoter-Luc plasmid was used, which as a kind gift from Martin Walsh (Addgene 
#33021).161  After 24 hours, transfection reagent was replaced with normal cell culture 
media containing ruxolitnib where indicated. Luciferase and Renilla activities were 
measured 24 h later using the Dual-Luciferase® reporter assay kit (Promega) according 
to the manufacturer's instructions on a BioTek Synergy 4 microplate reader using the 





CHAPTER 5 : REGULATION OF IFITM1 BY JAK/STAT SIGNALING IN AI-
RESISTANT BREAST CANCER  
This chapter is adapted from: 
 
Choi HJ & Lui A, Ogony J, Jan R, Sims P, Lewis-Wambi J. Targeting interferon 
response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-
induced cell death. Breast Cancer Res, 2015. 17(1): p. 6. PMCID:4336497. 
 
Lui A, Ogony J, Geanes E, Behbod F, Valdez K, Marquess J, Jewell W, Tawfik O, 
Lewis-Wambi J. IFITM1 suppression blocks proliferation and invasion of aromatase 
inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21. Cancer 
Lett. 2017 Apr 12;399:29-43.  
 
INTRODUCTION 
JAK/STAT signaling and ISGs 
Interferons (IFNs) are a class of glycoproteins known as cytokines that are 
produced by immune cells of most vertebrates and are secreted in response to viral 
infections, tumors, and other pathogenic microbial agents.72,162,163 IFNs diffuse to the 
surrounding cells and bind to high affinity cell surface type I (IFNα/β) and type II (IFNγ) 
receptors (IFNAR1/2), leading to phosphorylation and activation of JAK1, JAK2 and 
Tyk2. Activated JAKs phosphorylate and activate STAT1 and STAT2, resulting in the 
formation of STAT1/STAT1 homodimers and STAT1/STAT2 heterodimers. The dimers 
are transported to the nucleus by importins and bind to gamma associate sequences 
(GAS/STAT1) and IFN-stimulated response elements (ISREs) in ISG promoters to drive 
transcription.162,164,165  
Traditionally the STATs are phosphorylated and associate with interferon 
regulatory factor 9 (IRF-9) to form the phosphorylated interferon-stimulated gene factor 
3 (p-ISGF3) which enters the nucleus to initiate transcription at ISREs. Recently, 
however, studies have found that activity of the unphosphorylated STATs, which form 
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the unphosphorylated ISGF3 (U-ISGF3), are capable of stabilizing the ISGs in 
chemotherapeutic and radiation resistant cancers. 6,54 The interferon signaling pathway 
plays an important role in the proper functioning of the immune system and there is 
strong evidence that its dysregulation, resulting in constitutive overexpression of ISGs 
contributes to tumorigenesis and drug resistance. 69,75,114 
IFITM1 expression is classically driven by type 1 IFN mediated JAK/STAT 
signaling.2,66,72 Notably, enhanced STAT protein expression and activation have been 
linked to breast cancer development, progression and therapeutic resistance.54,67,69,126 
In contrast, the suppressors of cytokine signaling (SOCS) family of proteins specifically 
inhibits STAT phosphorylation. Silencing and down-regulation of SOCS proteins has 
been associated with breast cancer while high SOCS expression confers a better 
prognosis for patients.81-84 IFITM1 overexpression is likely one of the ways that 
JAK/STAT signaling drives breast cancer development, aggression and therapeutic 
resistance.  
JAK/STAT signaling itself is pro-survival and has been shown to confer 
resistance to chemotherapy and radiation in breast cancer.54,75 Increased signaling 
through this pathway also offers one potential method of maintaining estrogen-
independent growth in AI-resistant cancer cells.80 In this chapter we utilize the JAK1/2 
inhibitor ruxolitinib (Afinitor™) to assess the role of JAK/STAT signaling in IFITM1 
expression. Ruxolitinib is also FDA approved for the treatment of myelofibrosis. Here we 
also investigate whether oral ruxolitinib treatment can be used to target IFITM1 in vivo 
using orthotopic tumor xenografts. We demonstrate that ruxolitinib therapy holds 
promise for IFITM1-overexpressing ER+ and ER- breast cancers. 
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Mucin 1 (MUC1) in breast cancer 
The human mucin family consists of 21 that function to protect epithelial linings in 
the body. Mucin 1 (MUC1) is an O-glycosylated transmembrane heterodimer localized 
on the apical borders of epithelial cells.166-168 These glycoproteins can be either 
secreted or embedded in the plasma membrane where they contribute to the formation 
of mucous barriers, transmitting growth signals and promoting survival under stress.121 
The N-terminus supports the mucous layer, functions in cell adhesion and also aids in 
the trapping of microbes.169-171 The C-terminus of this protein is responsible for the 
intracellular signaling with links to diverse signaling molecules in the cytoplasm, nucleus 
and mitochondria that control cell proliferation and survival.166,172  
Due to the normal functions of MUC1 it is overexpressed in many epithelial 
cancers including breast, ovarian, lung, pancreatic, prostate, gastric, bladder and rectal 
carcinoma.173-178 The high levels of MUC1 allow movement of this protein from the 
apical surfaces to the entire cytoplasm, providing enhanced interaction with other known 
cancer modulators such as GSK3β, Wnt/β-catenin, NFκB, HER2 and p53.121,179-182 This 
diffuse expression of MUC1 contributes to invasion and metastasis by augmenting the 
epithelial to mesenchymal transition and encouraging attachment of carcinoma cells to 
distant sites by first interrupting adherens and tight junctions and then binding 
intracellular adhesion molecule 1 (ICAM-1) and e-selectin. 169,183 MUC1 is also known to 
act on the mitochondria and directly inhibit apoptosis by preventing the actions of Bcl-2-
associated X protein (Bax), preventing cleavage of caspase-8, release of cytochrome c 
and protecting from reactive oxygen species (ROS) induced mitochondrial 
changes.172,184,185 This allows MUC1 to confer resistance to death even in the presence 
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of hypoxia and chemotherapeutic drugs, making MUC1 overexpressing cancers a 
clinical challenge.186,187 MUC1 is overexpressed in approximately 90% of breast cancers 
and, due to its effect on invasion, metastasis and chemosensitivity, is associated with 
poor patient outcomes.121,188-192  
 The effect of MUC1 expression on prognosis is also largely due to the intimate 
relationship between MUC1 and hormonal signaling. MUC1 is known to bind directly to 
estrogen receptor alpha (ERα) in MCF-7 cells and enhance the activities of estrogen by 
preventing ubiquitination of ERα.193,194 MUC1 expression itself is also influenced by 
estrogen due to half an estrogen response element (ERE) in the promoter, making both 
MUC1’s levels and interactions hormonally controlled.120,195 Clinically, MUC1 expression 
correlates with ERα levels in breast tumors and also is associated with resistance to 
anti-hormonal therapy.193,196 189,197 In this chapter we investigate a connection between 
estrogen signaling, apoptosis and IFITM1 expression. 
MUC1 is also known to promote JAK/ STAT signaling by stabilizing 
phosphorylation of STAT1.67 STAT1 must be phosphorylated in order to enter the 
nucleus and function as a transcription factor.67,75 Here we investigate whether MUC1 
supports JAK/STAT signaling and IFITM1 expression in estrogen-independent MCF-
7:5C cells. It should be noted that MCF-7:5C cells undergo estrogen-induced apoptosis 
due to dysregulation of estrogen signaling. In fact, low-dose estrogen therapy is 
currently under clinical study as a potential treatment option for patients with AI-resistant 






IFNα drives overexpression of IFITM1 in AI-resistant MCF-7:5C cells by stimulating 
JAK/STAT signaling through IFNAR 
Binding of interferon alpha (IFNα) to the IFN alpha Type 1 receptor (IFNAR) 
complex initiates a signaling cascade comprising phosphorylation and dimerization of 
STAT1/2 molecules followed by their translocation to the nucleus, where they regulate 
the expression of ISGs. To investigate whether constitutive overexpression of IFITM1 in 
resistant MCF-7:5C cells is driven by the canonical IFNα signaling pathway, we first 
measured intracellular IFNα level in the supernatant and lysate of AI-resistant MCF-
7:5C and parental MCF-7 cells using ELISA. IFNα protein level was significantly higher 
in the supernatant and lysate of resistant MCF-7:5C cells compared to parental MCF-7 
cells (Figure 5.1A). IFNα mRNA expression was also significantly elevated in resistant 
MCF-7:5C cells compared to MCF-7 cells (Figure 5.1B). Canonically, STAT1 and 
STAT2 form a heterodimer when IFNAR is stimulated by type 1 IFNs. We confirmed 
that STAT1 and STAT2 both drove IFITM1 expression (Figure 5.1C). Next, we used a 
neutralizing antibody against the type 1 interferon receptor, IFNAR1/2, to see whether 
blocking the receptor reduces IFITM1 expression in the resistant cells. As shown in 
Figure 5.1D, α-IFNAR-Ab markedly reduced the basal expression of IFITM1 and 
PLSCR1 in resistant MCF-7:5C cells in addition to basal STAT1/2 phosphorylation.  
IFNAR neutralization also completely blocked exogenous IFNα induction of IFITM1 in 
parental MCF-7 cells.  
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We further tested whether suppression of the IFNα level is capable of reducing 
IFITM1 expression in the resistant cells. Induction of IFNα production is primarily 
controlled at the transcription level by the transcription factor IRF-7, hence, we  
  
(A) IFNα levels in MCF-7 and MCF-7:5C cells was measured in the supernatants and cell lysates by 
ELISA as described in Methods. All the illustrated data were performed in duplicate and are expressed 
as mean values of three independent experiments ± SD. (B) Measurement of IFNα mRNA was 
determined by real-time PCR. Fold change was calculated by means of the ΔΔCT method using PUM1 
as an internal control. Values are displayed as relative to MCF-7 cells and are means of triplicate 
measurements ± SD in three independent experiments. (D) MCF-7 and MCF-7:5C cells were treated 
with type 1 interferon receptor, IFNAR1neutralizing antibody and/or 100 IU IFNα. After 24 hoursm whole 
cell lysates ere immunoblotted for PLSCR1, IFITM1, p-STAT1/2 and STAT1/2.  (C) siRNA knockdown of 
STAT1 and/or STAT2 was conducted in MCF-7:5C cells. STAT1, STAT2 and IFITM1 expression was 
determined by immunoblotting.  
Figure 5.1 Elevated IFNa production drives constitutive overexpression of IFITM1 
through IFNAR 




performed siRNA knockdown of IRF-7 to suppress intracellular IFNα level in the 
resistant cells. We should note that IRF-7 mRNA and IRF-7 protein (Figure 5.2A) were 
constitutively overexpressed in resistant MCF-7:5C cells compared to parental MCF-7 
cells. IRF-7 siRNA markedly reduced and IFNα mRNA level and protein expression in 
resistant MCF-7:5C cells (Figure 5.2B) in addition to IFITM1 expression (Figure 5.2C). 
We also found that siRNA knockdown of IFNα reduced its protein level in the 
supernatant by 100% and in the lysate by 50% (Figure 5.2D). SiRNA knockdown of both 
IFNα and IRF-7 completely reduced IFITM1 protein expression in the resistant cells 
(Figure 5.2C). Taken together, these data indicate that IFNα is significantly elevated in 
the supernatant and lysate of AI-resistant MCF-7:5C breast cancer cells and that 
activation of the canonical IFNα/IFNAR signaling pathway plays a critical role in driving 
the constitutive overexpression of IFITM1 and other ISGs in the resistant cells. 
Dysregulation of type 1 IFNα signaling in AI-resistant 
Since IFITM1 and PLSCR1 were constitutively overexpressed in the resistant 
cells, we wanted to assess the functional integrity of the interferon signaling pathway in 
the resistant cells compared to parental MCF-7 cells. Cells were treated with 1,000 
IU/ml of IFNα for 0 to 24 hours and protein levels of IFITM1 and PLSCR1 were 
determined by Western blot analysis. We found that in parental MCF-7 cells, IFNα 
treatment significantly increased PLSCR1, IFITM1, protein expression in a time-
dependent manner with maximum induction at 24 hours of exposure (Figure 5.3A). In 
contrast, we found that IFITM1 and PLSCR1 were constitutively overexpressed in 
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resistant MCF-7:5C cells and that treatment with exogenous IFNα did not significantly 
increase the level of IFITM1 or PLSCR1 at any of the time points (<2-fold increase in 
  
(A) Whole cell lysates from MCF-7 and MCF-7:5C cells were immunoblotted for IRF-7 and IFITM1 
expression. B) Measurement of IRF-7 mRNA was determined by real-time PCR. Fold change was 
calculated by means of the ΔΔCT method using PUM1 as an internal control. Values are displayed 
as relative to MCF-7 cells and are means of triplicate measurements ± SD in three independent 
experiments. (b) The effect of IRF-7 knockdown on IFNα expression is determined by RT-PCR and 
ELISA. (c) The effect of IFNα or IRF-7 knockdown on IFITM1 expression is sown by immunoblotting. 
(d) Confirmation of IFNα siRNA knockdown is determined by ELISA. *p <0.05 or **p <0.01.  
Figure 5.2 IFNα  production is driven by interferon regulatory factor 7 (IRF-7). 
D 




PLSCR1 and IFITM1 at 24 hours) (Figure 5.3B). A similar trend was observed at the 
mRNA level for IFITM1 andPLSCR1 in resistant MCF-7:5C cells compared to parental 
MCF-7 cells (Figure 5.3C and Figure 5.3D). In MCF-7 cells, exogenous IFNα induced 
IFITM1 mRNA by approximately 374-fold, PLSCR1 mRNA by approximately 9-fold and 
STAT1 mRNA by approximately 11-fold at 48 hours, whereas, in resistant MCF-7:5C 
cells, treatment with IFNα induced IFITM1 mRNA by approximately 3-fold, PLSCR1 
mRNA by approximately 2-fold, and STAT1 mRNA by approximately 2-fold. Similar 
results were seen when assessing IFIT1, IFI27, MX1 and OAS1 expression in MCF-7 
and MCF-7:5C cells after 48 hours IFNα exposure (Figure 5.3E). These findings 
suggest that IFITM1 and other ISGs are constitutively overexpressed in the resistant 
cells due to dysregulation of interferon signaling, whereas, in parental MCF-7 cells, the 
interferon signaling pathway functionally intact and the induction of IFITM1 and other 
ISGs is tightly controlled. 
STAT proteins use ISRE and GAS motifs to drive IFITM1 expression 
Next, we investigated the ISRE and GAS transcriptional activity in the AI-
resistant MCF-7:5C cells. Luciferase reporters with tandem GAS/STAT1 or ISRE motifs 
indicated that there was basal activity of both types (Figure 5.4A and Figure 5.4C). 
Knockdown of STAT1 and STAT2 abrogated both GAS and ISRE activity. Interestingly, 
knockdown of both STATs equally inhibited transcription at ISRE sites while STAT1 
knockdown was more efficient at inhibiting GAS activity. These results suggest that both 
STAT1 and STAT2 may drive transcription at GAS and ISRE sites in MCF-7:5C cells. 




MCF-7 and MCF-7:5C cells were treated with 100 I/U IFNα for 0-72 hours. (A and B) Whole cell 
lysates were harvested at the indicated time points and immunoblotted for PLSCR1 and IFITM1 
expression. (C and D) Measurement of IFITM1 and PLSCR1 mRNA over time was determined by real-
time PCR. Fold change was calculated by means of the ΔΔCT method. Values are displayed as 
relative to day 0 and are means of triplicate measurements ± SD in three independent experiments. 
Figure 5.3 ISG expression in MCF-7 and MCF-7:5C cells in response to IFNα  
exposure. 




dramatically reduced GAS and ISRE activity in MCF-7:5C cells underscoring the 
importance of STAT activation in JAK/STAT signaling (Figure 5.4B and Figure 5.4D). 
Notably, IFITM1 promoter luciferase assay indicated that JAK/STAT signaling drove 
IFITM1 expression in MCF-7:5C cells. Knockdown of STAT1 and STAT2 both 
significantly inhibited IFITM1 transcription and IFNAR neutralization and Rux treatment 
had similar effects (Figure 5.4E).  
To determine which specific promoter elements drive IFITM1 transcription we 
conducted an analysis of the IFITM1 promoter sequence using MatInspector 
(Genomatix). MatInspector identified several promising ISRE and STAT1 motifs, with 
one potential STAT1/GAS sequence at -3157 and an ISRE sequence at the -1 
upstream from the transcription start site also being supported binding locations from 
other deposited data (Figure 5.5A). The IFITM1 promoter is classically about 750 kb 
and so we used chromatin immunoprecipitation (ChIP) assays to assess STAT1 and 
STAT2 binding at the suggested ISRE motif. ChIP assays determined that both STAT1 
and STAT2 bind to the IFITM1 promoter at the -1 position and that this binding is 
specific to activated STATs (Figure 5.5B). There was significantly higher STAT1 and 
STAT2 recruitment to this site in MCF-7:5C than in MCF-7 cells (Figure 5.5B) and 
inhibition of STAT phosphorylation with Rux dramatically reduced STAT protein 
recruitment (Figure 5.5C).  Taken together, these data highlight the abnormal 






Relative transcriptional activity at gamma associated sequence (GAS) sites is determined by 
luciferase assay (A) before and after STAT1/2 siRNA transfection or (B) Rux treatment in MCF-7 
and MCF-7:5C cells. Relative transcriptional activity at interferon stimulated response elements 
(ISRE) is determined by luciferase assay (C) before and after STAT1/2 siRNA transfection or (D) 
Rux treatment in MCF-7 and MCF-7:5C cells. (E) Relative transcriptional activity at the IFITM1 
promoter before and after IFNAR neutralization, Rux treatment or STAT1/2 siRNA transfection is 
determined by IFITM1 promoter luciferase reporter.   





(a) ISRE and GAS binding site were identified in the IFITM1 promoter in silico using MatInspector 
(Genomatix). (b) Fixed MCF-7 and MCF-7:5C cell lysates were subjected to chromatin 
immunoprecipitation (ChIP) with antibodies against STAT1, STAT2, MUC1 or species specific IgG 
control. (c) Fixed whole cell lysates from MCF-7:5C cells treated with 10μM Ruxolitinib/Jakafi (Rux) 
for 24 hours. qPCR was performed on the isolates DNA using primers designed to amplify the ISRE 
regulatory regions. Recruitment of the indicates proteins to the ISRE site was compared to input 
DNA and displayed as mean ± SD of technical triplicates in two independent experiments. 
Figure 5.5 STAT1, STAT2 and MUC1 are recruited to an ISRE in the IFITM1 promoter 
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IFITM1 can be targeted through JAK/STAT inhibition with Ruxolitinib (Jakafi™) in vivo 
We previously reported that the FDA approved JAK inhibitor, Ruxolitinib 
(Jakafi™) dramatically reduced STAT1 phosphorylation and IFITM1 expression in the 
MCF-7:5C cells (Figure 5.4A). To determine whether Rux may have potential clinical 
relevance for IFITM1-expressing breast cancer, we used the orthotopic model to 
determine whether IFITM1 can be targeted in vivo by Rux. IFITM1-null MCF-7 and 
IFITM1-expressing MCF-7:5C cells were transplanted into the 4th mammary fat pad of 
female NSG mice and after 25 days mice were randomized to receive either vehicle 
(Control) or 50 mg/kg ruxolitinib  by oral gavage. Rux treatment reduced STAT1 
phosphorylation in MCF-7:5C tumors (Figure 5.6B) and caused a reduction in MCF-
7:5C tumor growth while having little effect on MCF-7 tumor size (Figure 5.6C and 
Figure 5.6D). Immunohistochemistry confirmed that IFITM1 and phosphorylated STAT1 
(p-STAT1) were lost in the MCF-7:5C tumors (Figure 5.6E). Notably, Rux treatment of 
IFITM1 expressing MDA-MB-468 tumors also resulted in smaller tumor size and loss of 
IFITM1 expression (Supplemental Figure 6). These data suggest that IFITM1 
expression may define a subset of breast tumors that are sensitive to therapies that 





(a) Whole cell lysates from MCF-7 and MCF-7:5C cells treated with 10μM Ruxolitinib/Jakafi™ (Rux) 
for 24 hours were immunoblotted for phospho-STAT1 (p-STAT1), STAT1 and IFITM1 protein 
expression.  (b) 3 million MCF-7 or MCF-7:5C cells were injected into the 4th mammary fat pad of 
female NSG mice. After 22 days of tumor growth, mice were randomized to treatment groups and half 
were given 50 mg/kg Rux by oral gavage every other day. Tumor expression of phospho-STAT1 (p-
STAT1), STAT1 and IFITM1 after 21 days of treatment was determined by immunoblot. (c) Tumors 
were measured by digital calipers and tumor volume (mm3) displayed over time. (d) At the end of the 
experiment tumors were excised and tumor volumes were determined by digital caliper measurement. 
(e) Tumors were fixed, embedded in paraffin and sectioned onto glass slides. Hematoxylin and Eosin 
(H+E) staining revealed tumor architecture and IFITM1 and phospho-STAT1 (p-STAT1) expression 
was determined by immunohistochemistry. 
Figure 5.6 Inhibition of JAK/STAT signaling with Ruxolitinib decrease IFITM1 
expression and reduced the growth of aromatase inhibitor-resistant MCF-7:5C tumors 





MUC1 expression is dysregulated in AI-resistant MCF-7:5C cells 
Since MUC1 is one of the most overexpressed proteins in breast cancer and is 
known to interact with JAK/STAT signaling, we next investigated whether MUC1 was 
actually expressed in MCF-7:5C cells. We found that MUC1 is more highly expressed in 
AI-resistant MCF-7:5C cells than in expressed in parental MCF-7 cells (Figure 5.7A). 
Notably, another estrogen-independent clone, MCF-7:2A, that does not express IFITM1 
or have constitutive JAK/STAT signaling also expressed MUC1 at low levels (Figure 
5.7A). MUC1 is an estrogen-responsive gene that is normally transcribed in response to 
estrogen exposure so we next investigated the hormonal regulation of MUC1 
expression in MCF-7:5C cells. Treatment with 1nM estradiol (E2) significantly reduced 
MUC1 expression at the protein and mRNA level which is directly in contrast to the 
effect of E2 on MCF-7 cells (Figure 5.7). Treatment with the pure anti-estrogen 
fulvestrant (FUL or ICI) had the opposite effect and instead increased MUC1 mRNA and 
protein expression in MCF-7:5C cells (Figure 5.7). These data indicate that MUC1 
expression is hormonally controlled in a manner in direct contrast to canonical 
regulation and is unique to IFITM1 overexpressing AI-resistant breast cancer cells. 
MUC1 stabilizes JAK/STAT signaling which is necessary for IFITM1 expression 
It should be noted that JAK/STAT signaling is also known to contribute to MUC1 
expression. We found that both STAT1 knockdown and Rux treatment reduce IFITM1 
and MUC1 expression indicating that in the MCF-7:5C cells, constitutive JAK/STAT 
activation helps to maintain MUC1 expression in the absence of estrogen (Figure 5.8A). 
Next, we investigated whether MUC1 plays a role in IFITM1 expression. Co-




Figure 5.7 MUC1 expression is dysregulated in MCF-7:5C cells 
(a) Whole cell lysates for MCF-7, MF-7:5C and MCF-7:2A cells were immunoblotted for MUC1, p-
STAT1, STAT1 and ERα expression. (b) MCF-7:5C cells were treated with 1nM estradiol (E2) or 1uM 
fulvestrant (FUL). MUC1 mRNA expression was determined by RT-PCR at 0, 24, 48 and 72 hours. 
Fold change was calculated by the ΔΔCT method. Values are displayed as relative to day 0 and are 
means of triplicate measurements ± SD in two independent experiments. (c) Whole cell lysates were 
collected at 0, 12 and 24 hours and immunoblotted for MUC1 and ERα protein expression. (d) MCF-7 
and MCF-7:5C cells were treated with 1nM estradiol and fixed after 24 hours. Immunofluorescent 
staining was used to asses MUC1 and ERα expression and localization. *p<0.05 ** p<0.01 
** ** 
** * * 
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Notably, when STAT1 is not phosphorylated (Rux treated) MUC1 binding is significantly 
reduced, suggesting that STAT1 must be phosphorylated prior to MUC1 interaction 
(Figure 5.8B). Loss of MUC1 activity either with siRNA knockdown or treatment with the 
MUC1 inhibitor GO-201 reduced STAT1 phosphorylation and IFITM1 expression 
(Figure 5.8C and Figure 5.8D). This result indicates that MUC1 stabilizes the 
phosphorylation status of STAT1 protein and that this phosphorylation is required for 
IFITM1 transcription. Significantly, MUC1 knockdown reduced IFITM1 mRNA 
expression and transcription (Figure 5.8E and Figure 5.8F).  
MUC1 knockdown enhances estrogen-induced death through additive inhibition of 
IFITM1 expression 
Since we have previously reported that loss of IFITM1 induces cell death of AI-
resistant MCF-7:5C cells, we next investigated the effect of MUC1 knockdown on cell 
survival. Annexin V/ PI staining revealed that MUC1 knockdown also induces cell death, 
likely due to the inhibition of IFITM1 expression that results (Figure 5.9A). Here, we 
reported that estradiol treatment reduces MUC1 expression, which is critical to the 
maintenance of JAK/STAT signaling and IFITM1 expression in AI-resistant MCF-7:5C 
cells. Notably, MUC1 knockdown enhanced estrogen-induced death, suggesting a role 
for targeting MUC1 in conjunction with estrogen therapy (Figure 5.9B). We then 
determined whether estradiol directly affected IFITM1 expression and found that indeed, 
estradiol exposure reduced IFITM1 expression over time (Figure 5.9C). This finding is 
consistent with previous reports that estrogen induces apoptosis in MCF-7:5C and other 
LTED cell lines and tumors. We conclude that IFITM1 loss may be one of the 
mechanisms of estrogen-induced apoptosis which explains why both MUC1 knockdown 
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and estrogen treatment induce cell death. Finally, we conducted in silico analysis of 
deposited tumor expression data at cbioportal.org and we found that MUC1 and IFITM1 
overexpression co-occurs in 4 separate breast cancer datasets (Figure 5.10).  
  
Figure 5.8 MUC1 stabilizes JAK/STAT signaling through interaction with p-STAT1 
(a) MCF-7 and MCF-7:5C cells were either transfected with STAT1 siRNA or treated with 10μM 
Ruxolitinib/Jakafi (Rux). Whole cell lysates were immunoblotted for MUC1, p-STAT1, STAT1 and 
IFITM1 expression. (b) Whole cell lysates from MCF-7:5C cells treated with vehicle (Con) 10μM 
Ruxolitinib/Jakafi (Rux) for 24 hours were immunoprecipitated with anti-MUC1 antibody or rabbit IgG 
and samples immunoblotted for MUC1, ERα, p-STAT1 and STAT1 protein interaction. MCF-7 and 
MCF-7:5C cells were transiently transfected with MUC1 siRNA  (c)  or treated with MUC1 inhibitor 
(GO-201) (d). After 24 hours, MUC1, p-STAT1, STAT1 and IFITM1 expression were determined by 
immunoblotting. (e) MCF-7:5C cells were transiently transfected with control or MUC1 siRNA or 
treated with Rux. After 24 hours, mRNA expression of IFITM1 was determined by RT-PCR. (f) 
IFITM1 promoter activity was measured by luciferase assay in MCF-7:5C cells transiently 





(a) MCF-7 andMCF-7:5C cells were imaged at 20X 72 hours after transient transfection with 
control (siCon) or MUC1 (siMUC1) siRNA and the percent of dead cells was determined by 
AnnexinV/PI Staining (right panel). (b) After transient siCon or siMUC1 transfection, MCF-7:5C 
cells were treated with 1nM estradiol (E2) for  72 hours and the percent dead cells measured by 
Annexin V/PI staining (quantified in right panel). (c) Whole cell lysates from MCF-7:5C cells were 
treated with 1 nM E2 for 0-72 hours and immunoblotted for MUC1, PARP, p-STAT1, STAT1, and 
IFITM1 expression. *p<0.05 ** p<0.01 
 




Figure 5.10 MUC1 and IFITM1 co-occur in breast cancer 
(a) In silico analysis of tumor gene expression using the cbioportal.org database for deposited 
breast tumor expression for both MUC1 and IFITM1 expression resulted in four datasets with 
singificant overexpression of both proteins. (b) Fisher Exact test on each of the four datasets was 




Inflammation is often thought of as a double edged sword in the human body. While 
it is known that uncontrolled inflammation in general causes disease, we also know that 
some inflammatory response is necessary for the clearing of infections and the healing 
of wounds. In cancer, inflammation has also exhibited this contradiction. The role of 
inflammation in increasing the risk for gastrointestinal cancers is well accepted. 
Alternatively, the presence of inflammatory cells in other solid tumors has been 
established as a positive prognostic sign because it indicates the successful anti-tumor 
activity of the immune system. One possible reason for this contradiction is the lack of 
distinction between an inflammatory immune response and an IFN-related gene 
signature within a tissue.53 While inflammation and IFN signaling is necessary for the 
cells of the immune system to launch a successful defense against pathogens and 
tumors, it also seems to aide epithelial cells in altering their restraints on growth and 
proliferation, ultimately resulting in cancer.198,199 The majority of studies into the 
relationship of IFNs to the cancer process focus on the actions of IFNγ on the immune 
system and tumors themselves but the actions of type I IFNs are less well-known. 
Short-term AI-therapy has been shown to induce an inflammatory gene signature in 
breast cancer patients but mechanisms remain unclear. 200 Within a cancer cell, the 
type I IFN pathway is one of the systems that can be utilized to promote survival. In 
several types of solid cancers, a number of ISGs have been implicated in DNA damage 
resistance, making the tumor insensitive to chemotherapy and radiation (Table 1.1).  
Here, we found that IFITM1 overexpression is mediated by constitutive 
production of IFNα which drives JAK/STAT signaling through IFNAR. We reported that 
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STAT1 and STAT2 are continually phosphorylated which allows for continual 
transcription at ISRE and GAS motifs in AI-resistant cells, especially an ISRE sequence 
directly adjacent to the IFITM1 transcription start site. The fact that knockdown of IFNα 
dramatically reduced IFITM1 expression in the resistant cells and its loss significantly 
Figure 5.11 The role of MUC1 in JAK/STAT mediated IFITM1 overexpression and 
estrogen-induced apoptosis 
(a)In MCF-7:5C cells IFITM1 expression is stimulated by JAK/STAT signaling from IFNAR. Mucin 1 
(MUC1), an estrogen receptor (ERα) controlled gene is constitutively expressed by 
ligandindependent activity of ERα. MUC1 is expressed on cellular and mitochondrial membranes 
wherer it inhibits apoptosis. IFITM1 and other ISGs may also be present on the mitochondrial 
membrane to prevent apoptosis. MUC1 is cleaved at the membrane and the C-terminus of MUC1 
(MUC1-CT) binds to and stabilizes STAT phosphorylation. Upon estrogen exposure, MUC1 is lost 




induced cell death highlights the potential dependency of the resistant cells on elevated 
IFNα to maintain their resistant phenotype and to drive the constitutive overexpression 
of IFITM1 and the other ISGs in the cells. We should note that elevated IFN production 
has previously been reported in many pathological conditions, such as chronic 
inflammation and cancer, as well as in virus infections.201 In cancers, IFN production is 
thought to be increased by infiltrating immune cells or by the cancer cells 
themselves.72,202 Notably, we also discovered that MUC1 promotes IFITM1 expression 
by stabilizing the phosphorylated status of STAT1 in MCF-7:5C cells. MUC1 expression 
itself is dysregulated in the MCF-7:5C cell line, with estrogen treatment reducing not 
only MUC1 expression but also IFITM1 during estrogen-induced death.  These data 
underscore the key role that MUC1 plays in driving JAK/STAT mediated IFITM1 
overexpression (Figure 5.11). It is possible that combination of IFITM1 and MUC1 
inhibition may hold promise as the basis of a novel therapy for AI-resistant breast 
cancer.  
Ruxolitinib (Jakafi®) is a JAK1/2 inhibitor that prevents STAT phosphorylation 
and is currently approved by the FDA for treatment of myelofibrosis. We have found 
previously that IFITM1 expression in breast cancer is driven by IFNα production and 
constitutive JAK/STAT activity.59,73 Ruxolitinib treatment prevents IFITM1 expression 
and is currently being investigated in clinical trials as an alternative therapy in treatment-
refractory breast cancer (NCT01562873, NCT02041429, NCT01594216). Our study 
suggests that high IFITM1 expression may define a subset of breast cancer that is most 
sensitive to ruxolitinib therapy. In fact, we have found that oral ruxolitinib treatment can 
cause shrinkage of MCF-7:5C xenografts. We and others propose that harnessing 
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ruxolitinib therapy for use in treatment of solid tumors should be explored.203  It should 
be noted that ruxolitinib treatment is associated with several side effects including 
anemia, neutropenia, thrombocytopenia, dizziness and gastrointestinal distress. 
Additionally, ruxolitinib suppresses the immune system and there is concern for 
increased susceptibility to infection. This study suggests that MUC1 overexpression 
may also help define the subset of ISG-dependent breast cancers and that MUC1 
inhibition could be developed for treatment of ISG-overexpressing breast cancer. 
Developing alternative methods for inhibiting IFITM1 will require further study into the 
drivers of IFITM1 overexpression and a better understanding of structure and function of 
this protein.  
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MATERIALS AND METHODS 
ELISA 
Measurement of human interferon-α (IFNα) was conducted by ELISA (PBL Interferon 
Source, Piscataway, NJ).  One million MCF-7 or MCF-7:5C cells were seeded in 6-well 
plates and allowed to acclimatize overnight. Cells and supernatants were harvested 
after 24 hours and kept at -80°C until analysis. Protein was extracted by sonication in 
RIPA buffer supplemented with protease and phosphatase inhibitors. Supernatants and 
lysates were purified by centrifugation and analyzed for the presence of IFNα according 
to the manufacturer’s instructions. 
IFNAR neutralization 
In order to achieve neutralization of IFNAR, cells were pretreated with 5μg/mL anti-
IFNAR2/MMHAR2 from Millipore, Temecula, CA (cat# MAB1155) for 4 hours and then 
overnight with 20 U/mL human recombinant IFNα (Sigma) or 1nM E2 (Sigma) where 
indicated. Cells were harvested by cell scraping for western blot and by trypsinization 
for cell viability analysis with trypan blue. 
Luciferase Assays 
For Gamma Associated Sequence (GAS/STAT1) assays and Interferon Stimulated 
Response Element (ISRE) assays, the Cignal™ Reporter Assay (#CCS-009L and 
#CCS-008L) were used for analysis of STAT1/STAT1 homodimer and STAT1/STAT2 
heterodimer transcriptional activity, respectively and was utilized according to 
manufacturer’s instructions. Briefly, the reverse transcription protocol was used where 
cells were suspended in Opti-MEM and seeded in 96-well plates on top of already 
aliquoted transfection cocktail.  This cocktail contained Lipofectamine 2000™ and the 
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GAS Reporter, which is a mixture of an inducible reporter plasmid containing tandem 
GAS-responsive elements upstream of a firefly luciferase construct and a constitutively 
expressing Renilla luciferase construct. After overnight incubation, the mixture was 
replaced with normal media containing Ruxolitinib where indicated. Luciferase and 
Renilla activities were measured 24 h later using the Dual-Luciferase® reporter assay 
kit (Promega) according to the manufacturer's instructions on a BioTek Synergy 4 
microplate reader using the Gen 5 data analysis software (BioTek Instruments).  
Co-immunoprecipitation 
For co-immunoprecipitation (CoIP) experiments, cell lysates were collected in RIPA 
buffer supplemented with protease and phosphatase inhibitors and sonicated on ice. 
Cell lysates containing equivalent protein concentrations (5 µg) were pre-cleared with 
50:50 Protein A/G coated magnetic beads (Roche Diagnostics) then incubated 
overnight at 4°C with 2 µg appropriate antibody or control IgG. 50:50 Protein A/G coated 
magnetic beads were then added for the final 1 h of incubation time. Immune 
complexes were washed three times with PBS and, resuspended in Laemmli sample 
buffer containing dithiothreitol and β-mercaptoethanol (Initrogen) boiled for 5 min and 
subjected to western blotting analysis. 
Chromatin Immunoprecipitation (ChIP) Assay 
ChIP was performed using the ChIP-IT Express Kit (Active Motif) according to the 
manufacturer’s instructions using sonication as the method for chromatin shearing. 
Lysates were immunoprecipitated (IP) overnight (18 h) with the following antibodies 
STAT1, STAT2, MUC1 (Santa Cruz) or an equal amount of mouse or rabbit IgG. 
Resulting DNA was analyzed using qPCR as described previously 204, and data are 
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represented as a percentage of input DNA. In silico analysis using MatInspector 
(Genomatix) identified potential STAT1-binding sites and ISREs. 
Oral Treatment of Mice with Ruxolitinib 
See Orthotopic Cell Line Transplantation above.  
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SUPPLEMENTAL FIGURES  
Supplemental Figure 5.1 Inhibition of JAK/STAT signaling with Ruxolitinib (Jakafi) 
decreased IFITM1 expression and reduced the growth of IFITM1 overexpressing MDA-
MB-468 cells. 
3 million MDA-MB-468 cells were injected into the 4th mammary fat pad of female NSG mice. After 23 
days of tumor growth, mice were randomized to treatment groups and half were given 50 mg/kg Rux by 
oral gavage three times per week. (a) Tumors were measured weekly by digital calipers and tumor 
volume (mm3) displayed over time. (b) At the end of the experiment tumors were excised and final 
tumor volumes were determined by digital caliper measurement. (c) Immunoblotting on lysates from 
three tumors in separate mice determined expression of phospho-STAT3 (p-STAT3), STAT3 and 
IFITM1 after 42 days of treatment. (d) Tumors were fixed, embedded in paraffin and sectioned onto 
glass slides. Hematoxylin and Eosin (H+E) staining revealed tumor architecture and IFITM1 and 
phospho-STAT3 (p-STAT3) expression was determined by immunohistochemistry. 
 
Lui et al. Cancer Letters Cancer Letters. 
2017 Apr 12;399:29-43  
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CHAPTER 6 : CONCLUSION AND FUTURE DIRECTIONS 
This thesis demonstrated that overexpression of the ISG IFITM1 is driven 
through constitutive hyperactivation of JAK/STAT signaling which promotes AI-resistant 
breast cancer cell aggression and survival (Figure 6.1).  The MIND model served as a 
tool for assessing invasion in vivo in addition to reflecting the effect of IFITM1 on 
proliferation and survival seen in the orthotopic model. Loss of IFITM1 caused cell death 
through an induction of p21 transcription and nuclear translocation (Figure 4.5 and 
Figure 6.1).  Future studies are needed to determine the role that IFITM1 plays in p21 
cellular localization. Our data suggests that IFITM1 may be a targetable marker of 
aggressive breast cancer and that development of an IFITM1 specific inhibitor may hold 
promise for treatment refractory breast cancer. Until that therapy is developed, this work 
suggests that some combination of estrogen therapy with MUC1 or JAK/STAT inhibition 
can be harnessed as an alternative therapy for AI-resistant breast cancer. MUC1 and 
JAK inhibitors are currently under study in clinical trials for stage IV breast cancer. 
Type I interferons (IFNs αand β) are known to drive the expression of ISGs that 
encode proteins that possess anti-viral, anti-proliferative, pro-apoptotic and pro-
inflammatory functions; however, many experimental data have shown that high 
expression of IFN-induced genes, including STAT1 itself, promotes tumor growth, 
metastasis and resistance to chemotherapy and radiation.67-69,126,205 Normally, IFNs 
induce rapid activation of STATs through phosphorylation on the C-terminal tyrosine 
residues (Y701 for STAT1 and Y690 for STAT2) which drives the expression of ISGs.206 
Several important negative feedback mechanisms collaborate to terminate the 
expression of these genes several hours after IFN stimulation; for example, expression 
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of the potent negative regulator SOCS1 is rapidly induced by IFNs.207 Sustained 
expression of ISGs and their encoded proteins was previously thought to be deleterious 
to cell survival; however, recent studies suggest that sustained expression of a subset 
of ISGs and their encoded proteins might provide a survival advantage to cells.6,54 We 
should note that ER+ breast cancer cells are dependent on estrogen for survival and 
growth and when they are deprived of estrogen they tend to die. Long term, however, 
some breast cancer cells develop strategies to allow them to survive and grow in an 
estrogen-depleted environment.46,48,108 In our working model shown in Figure 6.1 
IFITM1 overexpression is driven by JAK/STAT signaling from IFNAR and is stabilized 
by MUC1., we propose that in AI-resistant MCF-7:5C breast cancer cells long term 
Figure 6.1 IFITM1 overexpression is driven by JAK/STAT signaling from IFNAR and is 
stabilized by MUC1. 
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estrogen deprivation induces the transcription factor and stress response gene IRF-7 to 
stimulate the production of IFNα which is then secreted from the cells and binds to the 
IFNAR1/2 to induce JAK/STAT signaling and the expression of ISGs (including IFITM1, 
PLSCR1, IFIT1, IFI21, OAS1, MX1, STAT1, STAT2, IRF-7, IRF-9). MUC1 stabilizes the 
constitutive JAK/STAT signaling in MCF-7:5C cells and allows for persistent STAT-
mediated transcription in the nucleus. We have found that IFITM1 promotes cell 
survival, AI-resistance and tumor proliferation and invasion. Thus, we propose that 
constitutive overexpression of the ISGs provides a survival advantage to the resistant 
cells that allows them to adapt and grow in an estrogen-depleted environment.  
There have been many studies into the mechanism(s) of AI-resistance which 
have revealed the role of several other cellular pathways that control cell proliferation, 
survival and growth. The proposed project differs from previous studies because of the 
unique model of AI-resistance that is being utilized and the distinctive cellular pathway 
that is altered in this model. Other popular models of AI-resistance rely upon artificial 
expression of the human aromatase enzyme, maintenance in cellular media that 
contains estrogen precursors and then long-term treatment with an aromatase 
inhibitor.208 Our model of AI-resistance more directly mimics what a breast cancer 
experiences during AI therapy. As breast epithelium does not normally express the 
aromatase enzyme, a breast cancer cell does not develop resistance by direct action of 
the drug but by depleting the circulating estrogen. A breast cancer cell experiences a 
sudden drastic decrease in the estrogen available for growth and proliferation. The 
simplicity of long-term estrogen deprivation makes our model more relevant. The other 
major difference in our system is the intrinsic up-regulation of type 1 IFN signaling in 
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direct response to estrogen deprivation. ISGs play a role in the progression of 
colorectal, pancreatic and ovarian cancer but the expression of ISGs has not been seen 
in previous models of breast cancer much less in AI-resistant breast cancer.  Our 
system provides a novel tool for investigating the novel role that this pathway plays in 
AI-resistance. Identification of another AI-resistant cell line that constitutively 
overexpresses IFITM1 remains a goal of the laboratory.  
Breast cancer can be separated into estrogen receptor/ progesterone receptor 
positive (ER+/PR+), Her2/neu positive (HER2+), and triple negative (ER-/PR-/HER2-) 
subtypes. We have, screened a panel of nine cell lines that represent all major subtypes 
of breast cancer and found IFITM1 overexpression in triple negative MDA-MB-468 and 
MDA-MB-157, and triple negative inflammatory SUM149 cells. Inflammatory breast 
cancer is a highly lethal subtype of breast carcinoma that may express any of the three 
aforementioned receptors. Notably, knockdown of IFITM1 in SUM149 cells using 
CRISPR/Cas9 dramatically reduces aggression in vitro and in vivo in a similar manner 
to AI-resistant MCF-7:5C cells. While there is marked inhibition of tumor proliferation 
and invasion, IFITM1 knockdown does not induce cell death in this model. We recently 
have also gained access to a triple negative breast cancer tissue microarray and found 
elevated IFITM1 expression as compared to normal breast tissue. Interestingly, this 
overexpression is most pronounced in TNBC tumors from African American (AA) 
patients. It should be noted the MDA-MB-468, MDA-MB-157 and SUM149 cell lines 
were all isolated from AA patients. Further studies by our laboratory into the role of 
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APPENDIX A: MANUSCRIPT-EVEROLIMUS DOWNREGULATES ESTROGEN 
RECEPTOR AND INDUCES AUTOPHAGY IN AROMATASE INHIBITOR-RESISTANT 
BREAST CANCER CELLS 
 
The PI3K/Akt/ mTOR pathway is one system that is thought to promote AI-resistance in 
breast cancer. As such, several inhibitors of this pathway are being investigated in 
clinical trials in various combinations with endocrine therapy with the goal of preventing 
or reversing resistance. In this study, we investigated the therapeutic benefits of the 
newest mTOR inhibitor to be approved by the FDA, everolimus/RAD001, in our models 
of AI-resistant breast cancer. 
 
Lui A, New J, Ogony J, Thomas S  and Lewis-Wambi, J. Everolimus downregulates 
estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer 





Background: mTOR inhibition of aromatase inhibitor (AI)-resistant breast cancer is 
currently under evaluation in the clinic. Everolimus/RAD001 (Afinitor®) has had limited 
efficacy as a solo agent but is projected to become part of combination therapy for AI-
resistant breast cancer. This study was conducted to investigate the anti-proliferative 
and resistance mechanisms of everolimus in AI-resistant breast cancer cells. 
Methods: In this study we utilized two AI-resistant breast cancer cell lines, MCF-7:5C 
and MCF-7:2A, which were clonally derived from estrogen receptor positive (ER+)  
MCF-7 breast cancer cells following long-term estrogen deprivation. Cell viability assay, 
colony formation assay, cell cycle analysis and soft agar anchorage-independent growth 
assay were used to determine the efficacy of everolimus in inhibiting the proliferation 
and tumor forming potential of MCF-7, MCF-7:5C, MCF-7:2A and MCF10A cells. 
Confocal microscopy and transmission electron microscopy were used to evaluate LC3-
II production and autophagosome formation, while ERE-luciferase reporter, Western 
blot, and RT-PCR analyses were used to assess ER expression and transcriptional 
activity. 
Results: Everolimus inhibited the proliferation of MCF-7:5C and MCF-7:2A cells with 
relatively equal efficiency to parental MCF-7 breast cancer cells. The inhibitory effect of 
everolimus was due to G1 arrest as a result of downregulation of cyclin D1 and p21. 
Everolimus also dramatically reduced estrogen receptor (ER) expression (mRNA and 
protein) and transcriptional activity in addition to the ER chaperone, heat shock protein 
90 protein (HSP90). Everolimus restored 4-hydroxy-tamoxifen (4OHT) sensitivity in 
MCF-7:5C cells and enhanced 4OHT sensitivity in MCF-7 and MCF-7:2A cells. Notably, 
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we found that autophagy is one method of everolimus insensitivity in MCF-7 breast 
cancer cell lines.  
Conclusion: This study provides additional insight into the mechanism(s) of action of 
everolimus that can be used to enhance the utility of mTOR inhibitors as part of 
combination therapy for AI-resistant breast cancer.  
KEYWORDS 






Estrogen deprivation using aromatase inhibitors (AIs) is currently the standard of 
care for patients with estrogen receptor-positive (ER+) breast cancer. Unfortunately, 
~30% of breast cancer patients develop resistance to AIs following long-term treatment 
209. The mechanism by which AI resistance develops is still not completely understood, 
however, several contributing factors have been identified including; alterations in ER 
signaling, enhanced growth factor signaling, and imbalance in the phosphoinositide 3-
kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway 29,30. 
The activation of the PI3K/Akt/mTOR pathway is considered clinically relevant for tumor 
escape from hormone dependence in breast cancer, promoting the survival of breast 
cancer cells in estrogen-deprived conditions.210 Additionally, upregulation of the 
PI3K/Akt/mTOR pathway is associated with poor outcome for breast cancer patients 
and has been observed in AI-resistant breast cancer models.155,211 As a result, a variety 
of PI3K/Akt/mTOR pathway inhibitors have been under study, including 
everolimus/RAD001 (Afinitor®).  
Everolimus is a rapamycin analog that is currently approved for treatment of 
metastatic breast cancer. It inhibits the PI3K/Akt/mTOR signaling pathway by preventing 
the phosphorylation of mTORC1, which interrupts the signaling cascade and results in 
inhibition of cell proliferation and growth.212 Everolimus treatment has shown promising 
anti-cancer effects in preclinical studies; however, when used as a single agent, it does 
not significantly decrease tumor size.213 As a result, recent clinical trials have focused 
instead on simultaneous targeting of the PI3K/AKT/mTOR and ER pathways in ER+ 
breast cancer.214-216 The results from these trials have been very encouraging due to 
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significant improvements in response rate and progression free survival for both AI-
sensitive and AI-resistant patients.217-219 Subsequent laboratory studies have focused 
on comparison of everolimus in combination with endocrine therapies 154,220 as well as 
other PI3K/Akt/mTOR inhibitors in a variety of breast cancer cell lines 153,221 and these 
studies have reported synergy between tamoxifen or AI therapy and everolimus. 
However, these studies have not investigated the anti-cancer mechanisms of 
everolimus alone in AI-resistant breast cancer cells.  
Everolimus and other PI3K/Akt/mTOR inhibitors are known to induce autophagy 
in both solid and blood tumors 222,223; however, to our knowledge, the phenomenon has 
not been reported in breast cancer. Autophagy allows cells to degrade dysfunctional 
organelles and proteins, and recycle their components. Autophagy can support tumor 
survival during treatment, making it a possible mechanism for AI-resistance.224,225 This 
process is dependent upon the cleavage of microtubule associated light chain 3 (LC3) 
to LC3-I and subsequent lipidation to LC3-II which allows for final formation of the 
autophagosome membrane.226 A group of small proteins, called heat shock proteins 
(HSPs), promote cell survival during stress reactions by promoting the refolding of 
denatured proteins and directly regulating autophagy. Specifically, HSP70 is thought to 
be required for the induction of autophagy 227,228 in response to inhibition of the 
PI3K/Akt/mTOR pathway by either starvation or rapamycin treatment 229,230. Another 
heat shock protein, HSP27, allows cells to survive a variety of cytotoxic stimuli 231,232 
and is thought to be degraded during starvation and rapamycin-induced 
autophagy.233 Due to the link between drug resistance and autophagy, we hypothesized 
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that the induction of autophagy may contribute to everolimus insensitivity in MCF-7 
breast cancer cell lines.  
In this study, we investigated the effects of everolimus, as a single agent, or in 
combination with 4-hydroxy tamoxifen (4-OHT) or chloroquine on cell proliferation, 
anchorage-independent growth, PI3K/Akt/mTOR signaling, ER expression and 
transcriptional activity, LC3 turnover, and autophagosome induction in AI-sensitive 
MCF-7 and AI-resistant MCF-7:5C and MCF-7:2A breast cancer cells.  We report that 
everolimus exerts similar anti-proliferative effects in both the AI-sensitive and AI-
resistant breast cancer cell lines and that its inhibitory activity is associated with G1 
arrest and down regulation of ERα expression. Everolimus also reverses and enhances 
4OHT sensitivity during long-term co-treatment of the AI-resistant cell lines. Lastly, we 
report that autophagy is a mechanism of everolimus insensitivity in MCF-7, MCF-7:5C 
and MCF-7:2A cells, possibly explaining the equal response of these cell lines to 
treatment. The information from this study may enhance future selection of everolimus 




MATERIALS AND METHODS 
Cell lines and culture conditions  
The MCF-7 cell line 42,132 was obtained from Dr. V. Craig Jordan (University of Texas 
MD Anderson Cancer Center, Houston) and maintained in RPMI-1640 medium 
supplemented with 10% fetal bovine serum, 2 mM glutamine, Antibiotic/Antimitotic mix, 
MEM Non-Essential Amino Acids (Invitrogen, Waltham, MA), and bovine insulin at 6 
ng/mL (Sigma Aldrich, St. Louis, MO). The long-term estrogen deprived human breast 
cancer cell lines; MCF-7:5C 42,48 and MCF-7:2A 122,132 were cloned from parental MCF-7 
cells following long term (> 12 months) culture in estrogen-free medium composed of 
phenol red-free RPMI-1640, 10% fetal bovine serum treated three times with dextran-
coated charcoal (SFS), 2 mM glutamine, bovine insulin at 6 ng/mL, Antibiotic/Antimitotic 
mix, and MEM Non-Essential Amino Acids (Invitrogen). The MCF10A cell line was 
purchased from the American Type Tissue Culture Collection. They are maintained 
in Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12) in a 1:1 
mixture and supplemented with 5% horse serum, Antibiotic/Antimitotic mix (100 IU/mL 
penicillin, 100 μg/mL streptomycin, 25 µg/mL of Fungizone® from Invitrogen, Grand 
Island, NY), 20ng/ml EGF (Millipore), 0.5mg/ml hydrocortisone, 100ng/ml cholera toxin 
(Sigma Aldrich). All cell lines were cultured at 37°C under 5% CO2. After overnight 
acclimatization period, cells were cultured with 20 nM everolimus alone or in 
combination with 1 μM 4-hydroxytamoxifen (Sigma Aldrich) or 50 μM Chloroquine 






Cells were assayed for viability in 24-well plates using the Cell-Titer Blue Assay Kit 
(Promega, Madison, WI) per the manufacturer’s instructions. Assay plates were kept at 
37˚C in 5% CO2 for 3 hours and read at 560-590 nM on a BioTek Synergy 4 microplate 
reader using the Gen 5 data analysis software (BioTek Instruments, Winooski, VT). 
Western blotting  
Cells were seeded in 6-well plates, collected using a cell scraper and suspended in 
RIPA buffer (Thermo Scientific, Pittsburgh, PA) supplemented with protease inhibitor 
cocktail and phosphatase inhibitor (Sigma Aldrich). Cells were homogenized over ice by 
sonication. After purification of the sample by centrifugation, protein concentration was 
determined by protein assay (Bio-Rad, Hercules, CA). The proteins were separated by 
4-12% SDS–polyacrylamide gel electrophoresis (SDS–PAGE) and electrically 
transferred to a polyvinylidene difluoride membrane (Santa Cruz Biotechnology). After 
blocking the membrane using 5% non-fat milk, target proteins were detected using 
either Anti-mTOR, anti-phospho-mTOR, anti- LC3A/B (Cell Signaling, Beverly, MA), 
anti-p70S6K, anti-phospho-p70S6K, anti-AKT, anti-phospho-AKT (S473) or anti-ERα 
(Santa Cruz Biotechnology) antibodies. Membranes were stripped and re-probed for β-
actin (Cell Signaling) or β-tubulin (Sigma Aldrich). The appropriate horseradish 
peroxidase (HRP)-conjugated secondary antibody was applied and the positive bands 
were detected using Amersham ECL Plus Western blotting detection reagents (GE 
Health care, Piscataway, NJ). In the case of LC3 analysis, cells were treated with 50 µM 
chloroquine (CQ) for 24 or 48 hours to allow for LC3-II accumulation. Immunoreactivity 
was detected using anti-mouse or anti-rabbit IgG conjugated to Dylight 680 or 800 
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fluorochromes (Thermo Scientific, Waltham, MA), respectively. Blots were visualized on 
Odyssey imager (LiCor, Lincoln, NE). Quantitation of immunoreactive signals was done 
by densitometry using ImageJ 1.46r software (NIH, Bethesda, MA).  The ratio of protein 
expression to β-tubulin in each lane was calculated and presented relative to the 
respective controls within each experiment.   
Cell Cycle Analysis 
Cells were incubated in the appropriate cell culture media with and without drug 
treatment. Cells were harvested at the indicated time points by trypsinization. They were 
washed once with cold PBS and stained with 50 µg/mL Propidium Iodide and 100 
µg/mL RNase A in PBS (Invitrogen).  Samples were analyzed using a BD FACSAria™ II 
Flow Cytometer (BD, Franklin Lakes, NJ) and the data were analyzed with FlowJo 
software (Ashland, OR). 
Clonogenic Proliferation Assay 
Cells were seeded at 1,000 cells per well in 6-well plate in singe cell suspension. After 
24 hour acclimatization, they were treated every three days and allowed to proliferate 
and establish colonies for 9 days. Cells were stained with 0.5% crystal violet in 1:7 
acetic acid: methanol and imaged at 1X in a Bio-Rad ChemiDoc™ XRS+ System with 
Image Lab™ Software (Bio-Rad Laboratories Inc., Hercules, CA). Colonies were 
counted and measured using Image J software (The National Institute of Health, 
Bethesda, MD). 
Soft Agar Anchorage-independent Growth Assay 
6-well plates were coated with 1 mL of 0.8% agarose in the appropriate culture media. 
Cells were then suspended in 0.48% agarose and immediately overlaid on the pre-
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coated plates.  Once the agarose was solid, 1mL of culture medium with or without 20 
nM everolimus was added and replaced every 4 days for 15 days. Cultures were then 
stained with 0.005% crystal violet in PBS, washed with PBS until the background was 
clear and imaged microscopically at 10X for measurement of colony diameter. Plates 
were also imaged at 1X in a Bio-Rad ChemiDoc™ XRS+ System with Image Lab™ 
Software (Bio-Rad). Colonies were counted and measured using Image J software 
(NIH).  
Real Time PCR 
Cells were seeded in 6-well plates and allowed to acclimatize overnight. Following 72 
hour treatment with 20 nM everolimus, cells were harvested by cell scraping in RLT 
lysis buffer and total RNA was isolated using the Qiagen RNeasy kit (Venlo, Limburg). 
First strand cDNA synthesis was performed from 3 μg total RNA using MulV Reverse 
Transcriptase (Applied Biosystems, Carlsbad, CA) on a Bio Rad MyCycler™. RT-PCR 
was conducted using the ViiA™ 7 Real-Time PCR system (Applied Biosystems) and 
SYBR Green Reagent (Life Technologies, Carlsbad, CA) with primers specific for ERα 
and the housekeeping gene PUM1. Primers for ERα: Forward 5’–
AAGAGGGTGCCAGGCTTTGT–3’, Reverse 5’–CAGGATCTCTAG CCAGGCACAT –3’. 
Primers for PUM1: Forward-TCACCGAGGCCCCTCTGAACCCTA    Reverse- 
GGCAGTAATCTCCTTCTGCATCCT (Integrated DNA Technologies, Coralville, Iowa). 
Relative ERα mRNA expression level was determined as the ratio of the signal intensity 
to that of PUM1 using the formula: 2-ΔCT. When treated with everolimus, fold change in 
ERα expression was normalized to PUM1 and then compared to the untreated value for 
that cell line using the formula: 2-ΔΔCT.  
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Luciferase Reporter Assay 
Cells were seeded in 12-well tissue culture plates overnight for attachment before 
transfection. The cells were transfected using Lipofectamine 2000™ Transfection 
Reagent (Invitrogen, San Diego) according to the manufacturer's recommendations. 
Briefly, 4μL of Lipofectamine 2000, 0.8 μg of ERE Luciferase plasmid DNA and 0.01 μg 
of the pRL CMV Renilla (Promega) were diluted individually in 250-μl aliquots of 
OptiMEM Reduced-Serum Medium (Invitrogen). Cells were incubated for 24 h after 
transfection, and then treated with 20 nM EVE or vehicle in complete media for 24 
hours. The Luciferase and Renilla activities were measured using the dual luciferase 
assay kit (Promega) according to the manufacturer's instructions. To confirm the 
specificity of the ERE Luciferase construct, EVE treated cells were also compared to 
those treated with 1nM 17β-estradiol and 1nM Fulvestrant, a pure anti-estrogen 
(Sigma). Relative Fluorescence Units (RFUs) were calculated as a ratio of Luciferase to 
Renilla signal intensity. The ERE Luciferase reporter construct was a kind gift from Dr. 
Clodia Osipo (Loyola University, Chicago, IL). 
Immunofluorescence microscopy 
Cells grown on glass coverslips were washed in PBS and fixed with 100% ice cold 
methanol for 10 minutes. After permeabilization by 0.1% Triton X-100 in PBS for 10 min, 
cells were incubated with 5% normal horse serum/PBS for 30 min, followed by 
incubation with ERα or LC3B antibody, 2 µg/mL in 0.01% Triton X-100 /PBS overnight 
(Santa Cruz Biotechnology). Cells were stained with fluorescein isothiocyanate (FITC)-
conjugated labeled goat anti-rabbit IgG (Cell Signaling), 4 µg/mL in PBS for 1 h, 
followed by coverslip mounting with the ProLong® Gold anti-fade reagent with DAPI 
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(Life Technologies). Samples were imaged on a Leica TCS SPE confocal microscope in 
the Confocal Imaging Core at The University of Kansas Medical Center. Images were 
collected and analyzed using the Leica LAS AF Lite software (Leica Biosystems, 
Nussloch, Germany). For quantification, mean fluorescent intensity was determined 
using Image J software on green (FITC) channel images. 
Electron Microscopy 
1 x106 cells were seeded in 6-well plates and treated after an overnight acclimatization. 
After 72 hours of treatment cells were harvested by scraping and fixed for 24 hours at 
4⁰C in 0.1 M cacodylate buffer supplemented with 2% glutaraldehyde. Samples were 
then processed in The Electron Microscopy Research Laboratory at KU Medical Center 
as follows. Briefly, cell pellets were washed in 0.1M cacodylate buffer for 10 min, and 
resuspended. Cell pellets were post fixed in 1% osmium tetroxide buffered in 0.1M 
cacodylate, rinsed in distilled water 3X’s and then dehydrated in a graded series of 
ethanol as follows: 50%,70%,80%,95%,100%,100% 10 min each step. Cells were 
placed into propylene oxide for 20 min, then into a 50:50 mixture of propylene oxide and 
Embed 812 resin medium overnight at room temperature. Samples were cured 
overnight in beem capsules at 60 degrees and then sectioned with a diamond knife on a 
Leica UC-7. Sections were cut at 80nm and contrasted with uranyl acetate and lead 
citrate and imaged on a JEOL 100CX II Transmission Electron Microscope (Tokyo, 
Japan).  
Statistical analysis 
At least three separate experiments were performed for each measurement unless 
otherwise indicated. All quantitative data were expressed as means with error bars 
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representing 1 standard deviation (mean ± 1SD). Comparisons between two treatments 
were analyzed using a two-way student t-test with P-value of < 0.05 considered to be 




Everolimus inhibits proliferation through induction of G1 arrest 
We tested the anti-proliferative effect of everolimus in two AI-resistant breast 
cancer cell lines, MCF-7:5C and MCF-7:2A and their parental AI-sensitive cell line, 
MCF-7. We found that everolimus inhibited the proliferation of MCF-7:5C and MCF-7:2A 
cells with relatively equal efficiency compared to MCF-7 breast cancer cells (Fig. 1a, 
upper panel). The IC50 values for MCF-7, MCF-7:5C and MCF-7:2A cells were 25 nM, 
38 nM and 20 nM, respectively, indicating only minor differences in sensitivity to 
everolimus between these cell lines (Fig. 1a, lower panel). Treatment with 20 nM 
everolimus achieved maximal inhibition of all three cell lines (Fig. 1a) as early as 24 
hours post-treatment (Fig. 1b). Additionally, the everolimus mediated inhibition of 
proliferation could be maintained with treatment every three days under clonogenic 
assay conditions (Fig. 1c).  In contrast, everolimus had no effect on the proliferation of 
the immortalized normal breast epithelium cell line, MCF10A (Additional File 1: Figure 
S1a and b).  
Cell cycle analysis of MCF-7, MCF-7:5C, and MCF-7:2A cells treated with 
everolimus indicated that the anti-proliferative effect of the drug was due to G1 arrest. 
The percentage of cells in G1 phase increased by at least 20% in all three cells lines as 
early as 24 hours after treatment (Fig. 2a) and this persisted through 72 hours (Fig. 2b). 
Everolimus had no effect on the cycling of the normal breast epithelial cell line MCF10A 
(Additional File 1: Figure S1c). Additionally, we found that the expression of cyclin D1 
and p21 were significantly reduced in MCF-7, MCF-7:5C and MCF-7:2A cells 48 and 72 
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hours after treatment (Fig. 2c). This data indicates that everolimus is effective at 
inhibiting the proliferation of breast cancer cells due to marked induction of G1 arrest. 
Everolimus reduces the anchorage-independent growth  
The ability of cancer cells to grow in an anchorage-independent manner is a 
critical marker of tumor forming and metastatic potential. We compared the abilities of 
MCF-7, MCF-7:5C and MCF-7:2A cells to grow in an anchorage-independent manner 
using the soft-agar 3D colony formation assay. We found that MCF-7:5C cells produced 
three times more 3D colonies than the MCF-7 and MCF-7:2A cells. Additionally, 20 nM 
everolimus significantly reduced the number of 3D colonies in all three cell lines (Fig. 
3a). The 3D colonies formed by the MCF-7:5C cells averaged 18 μM², while those 
formed by the MCF-7 and MCF-7:2A cells averages 40 and 35 μM² respectively. Upon 
microscopic inspection, we found that 20 nM everolimus dramatically reduced the size 
of 3D colonies in all three cell lines, with the most pronounced effect being on the MCF-
7:5C cells (Fig. 3b). These data indicate that everolimus inhibits not just the proliferation 
of breast cancer cells, but also their tumor forming and metastatic potential  
Effects of everolimus on the PI3K/Akt/mTOR pathway 
We also examined the effect of everolimus treatment on the activation of the 
PI3K/Akt/mTOR pathway. We found that everolimus significantly inhibited mTOR 
phosphorylation as early as 30 minutes post treatment but not Akt, p70S6K and 4EBP1 
(Fig. 4, upper panels). Everolimus inhibited the phosphorylation of downstream 
members of the PI3K/Akt/mTOR pathway at 12 hours. This was most prominent at 24 
hours in MCF-7, MCF-7:5C and MCF-7:2A cells (Fig. 4, bottom panels). 25 nM 
everolimus was sufficient to inhibit PI3K/mTOR/Akt signaling at 12 and 24 hours but 
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higher doses were more effective at blocking phosphorylation. Notably, inhibition of 
p70S6K phosphorylation was observed by 60 minutes in the AI-sensitive MCF-7 cell 
line, especially with higher doses, but not in the AI-resistant MCF-7:5C and MCF-7:2A 
cells until 12 hours post-treatment (Fig. 4). Reduction of phospho- mTOR, p70S6K and 
Akt were maintained by 20 nM everolimus through 48 and 72 hours (Additional File 2: 
Figure S2). Everolimus successfully targets the Akt/mTOR pathway in AI-sensitive and 
AI-resistant breast cancer cells. 
Everolimus reduces estrogen receptor (ER) expression and transcriptional 
activity  
The activity of ERα can be regulated by the PI3K/Akt/mTOR pathway and is 
critical to the survival and proliferation of AI-sensitive MCF-7 cells, as well as the AI-
resistant MCF-7:5C and MCF-7:2A cell lines. The ligand-independent activity of ER 
maintains the growth and survival of AI-resistant breast cancer cells.22,234 We found that 
treatment with everolimus significantly reduced ER transcriptional activity and protein 
expression (Fig. 5a and b). This was compared to the action of the pure anti-estrogen 
fulvestrant (Fig. 5a and b). Everolimus also dramatically reduced ERα mRNA 
expression (Fig. 5c) in addition to protein expression of the ER chaperone, HSP90 (Fig. 
5d). Downregulation of ER expression was confirmed by immunofluorescent confocal 
microscopy (Fig. 5e). Notably, there was higher ER transcriptional activity in AI-resistant 
MCF-7:5C and MCF-7:2A cells compared to parental MCF-7 cells, confirming estrogen-
independent ER action in the resistant cells (Fig. 5a). Taken together, these data 
indicate that everolimus, and therefore PI3K/Akt/mTOR signaling, is capable of 
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regulating ER expression and transcriptional activity in both wild-type MCF-7 cells and 
AI-resistant MCF-7:5C and MCF-7:2A cells.  
Everolimus reverses 4-OH tamoxifen resistance 
Due to earlier studies that have found synergy between tamoxifen and 
everolimus in endocrine-sensitive breast cancer cell models and patients, we 
investigated the efficacy of this combination in our MCF-7, MCF-7:5C and MCF-7:2A 
cells. We have previously shown that the AI-resistant MCF-7:5C cells are not 
responsive to 4OHT, whereas MCF-7:2A are partially sensitive to 4OHT.234 In this 
study, 1μM 4OHT significantly inhibited the proliferation of MCF-7 and MCF-7:2A cells, 
reducing the number of 2D colonies by 20% and 10% respectively, but had no effect on 
MCF-7:5C cells (Fig. 6a). Treatment with 20 nM everolimus for 9 days significantly 
reduced the proliferation of all three cell lines, reducing colony numbers by ~ 60% (Fig. 
6a). Co-treatment of MCF-7, MCF-7:5C and MCF-7:2A cells with 1μM 4OHT and 20 nM 
everolimus reduced colony formation in MCF-7 and MCF-7:2A cells by ~ 95% and also 
had added benefit in the 4OHT-resistant MCF-7:5C cells, bringing the anti-proliferative 
effect from 60% to 76%. Synergy between 4OHT and everolimus treatment was present 
despite reductions in ERα expression in all three cell lines (Fig. 6b). This data supports 
clinical observations that the combination of tamoxifen with everolimus has therapeutic 
benefit in patients with ER+ breast cancer and can re-sensitize AI-resistant breast 
cancer to endocrine therapy. 




We investigated whether everolimus treatment induced autophagy in MCF-7, 
MCF-7:5C and MCF-7:2A cells. We found that everolimus reduced the levels of HSP70 
and HSP27 in all three cell lines (Fig. 7a). Interestingly, everolimus also induced PARP 
cleavage (Fig. 7a); however, this was not associated with apoptosis by annexin v/PI 
staining (data not shown). Chloroquine was used as an autophagic flux inhibitor, and 
basal autophagy was assessed with and without everolimus treatment. Both 
immunofluorescent microscopy and western blot (Fig. 7b and 7c), indicate that 
everolimus markedly enhanced LC3-II above basal level, respectively. A lysosomal 
protease inhibitor cocktail (100 μM leupeptin, 10μg/mL pepstatin A and 10μg/mL e-64d 
for 24 hours) was also used to inhibit autophagic flux but results were not as robust as 
with 50 µM chloroquine (data not shown). As further indication of everolimus’ ability to 
induce autophagy, the number of autophagosomes identified by electron microscopy in 
all three cell lines was also increased (Fig. 8a and 8b). Combined inhibition of 
autophagy with 50 µM CQ significantly improved the efficacy of everolimus treatment on 
cell proliferation, indicating that autophagy is a method of everolimus insensitivity in 
MCF-7 cell lines (Fig. 8c). Under normal conditions, the MCF-7:5C cell line displayed 
dilated endoplasmic reticulum, and both AI-resistant cell lines had pleomorphic 
mitochondria, indicating that aberrant metabolism is likely part of the phenotype of these 
AI-resistant breast cancer models (Fig. 8a). These data suggest that MCF-7, MCF-7:5C 
and MCF-7:2A cells use autophagy as a method of everolimus resistance and that this 





Fig. 1 Everolimus inhibits the proliferation of AI-sensitive and AI-resistant breast cancer cells. 
(a) MCF-7, MCF-7:5C and MCF-7:2A cells were treated with 20 nM everolimus or vehicle (control) for 
72 hours. The percent of viable cells after everolimus treatment was determined by cell viability assay 
and compared to control. IC50 values for each of the cell lines were determined by nonlinear 
regression on normalized values. Values represent means of three experiments conducted in 
quadruplet. (b) MCF-7, MCF-7:5C and MCF-7:2A cells were seeded in 24-well plates and treated with 
20 nM everolimus or vehicle after overnight acclimatization (Day 0). The percentage of viable cells 
was determined at 24, 48, 72 and 96 hours post treatment by comparison to vehicle treated cells. (c) 
Cells were seeded in single cell suspension and allowed to proliferate for 9 days in the presence of 
20nM everolimus or vehicle (control). The plates were photographed at 1X magnification (left panel) 
and the number of colonies and colony size were quantified using Image J (right panel). Bar graphs 






Fig. 2 Everolimus induces G1 arrest. (a) MCF-7, MCF-7:5C and MCF-7:2A cells were treated for 24 
hours with 20 nM everolimus or vehicle and then harvested by trypsinization. Samples were fixed with 
methanol, stained with propidium iodide and analyzed by flow cytometry. The percent of cells in each 
phase of the cell cycle from a representative experiment are indicated in pie charts. (b) Samples from 
cells treated for 24, 48 and 72 hours are summarized in the table. Values are means from three 
independent experiments analyzed in duplicate and are displayed as mean ± SD. ** p< 0.01. (c) Cyclin 
D1 and p21 expression in MCF-7, MCF-7:5C and MCF-7:2A cells following treatment with everolimus 





Fig. 3 Everolimus reduces anchorage-independent growth. (a) MCF-7, MCF-7:5C and MCF-
7:2A cells were seeded in single cell suspension within a layer of 0.5% agarose gel. Cells were 
treated with 20 nM everolimus or vehicle every 48 hours for 17 days. Images were taken at 1X 
magnification and the number of colonies quantified using Image J. (b) Images of the same wells 
were taken at 10X magnification and colony diameter in μm2 is shown. Bar graphs represent the 







Fig. 4 Everolimus targets the mTOR/Akt pathway. AI-sensitive MCF-7 and AI-resistant MCF-7:5C 
and MCF-7:2A cells were treated with 25, 50 and 100nM everolimus. Phosphorylation of mTOR, AKT, 
p70s6K, 4EBP1 and total protein levels are shown at 30mins, 60mins, 12 and 24 hours. Images are 




  Fig. 5 Everolimus treatment inhibits estrogen receptor α expression and activity. (a) ER 
transcriptional activity after 24 hour treatment of MCF-7, MCF-7:5C and MCF-7:2A cells with 20 nM 
everolimus (EVE) and 1μM fulvestrant (FUL) is demonstrated using an ERE luciferase reporter. (b) 
Corresponding expression of estrogen receptor α (ERα) after 48 hours of treatment is shown by 
western blot. (c) RT-PCR demonstrates the impact of 20 nM everolimus on ERα mRNA production in 
all three cell lines after 24 hours. (d) The effect of everolimus treatment on mTOR phosphorylation as 
well as HSP90 and ERα expression is shown. (e) Immunofluorescent confocal microscopy illustrates 
the impact of 20 nM everolimus on ERα expression and localization (green). Cell nuclei are stained with 
DAPI (blue). Bar graphs represent means from two independent experiments analyzed in quadruplet 





Fig. 6 Everolimus enhances tamoxifen sensitivity. (a) MCF-7, MCF-7:5C and MCF-7:2A cells were 
seeded in single cell suspension and allowed to proliferate for 9 days in the presence of 20 nM 
everolimus, 1µM 4-hydroxy tamoxifen (4OHT) or vehicle for 48 hours. The plates were photographed 
and the number of colonies was quantified using Image J. Bar graphs represent the data from three 
independent experiments in triplicate and values are mean ± SD. *p<0.05, **p<0.01. *** p< 0.001. (b) 
Western blot indicates the effect of each treatment on mTOR phosphorylation and ERα, HSP90 




  Fig. 7 Everolimus modifies autophagic cell markers. (a) Inhibition of mTOR phosphorylation, 
downregulation of HSP70 and HSP27 as well as induction of PARP cleavage by 20 nM everolimus are 
shown by western blot. (b) MCF-7, MCF-7:5C and MCF-7:2A cells were treated with vehicle, 20 nM 
everolimus, 50µM chloroquine (CQ) or both for 24 hours. LC3B is shown by immunofluorescent 
confocal microscopy. Punctate LC3B granules (green) are indicated with white arrows. Cell nuclei are 
stained with DAPI (blue). Mean fluorescent intensity was determined using Image J. (c) Cells were 
treated with vehicle, 20 nM everolimus, 50µM chloroquine (CQ) or both for 48 hours and LC3-I and -II 
assessed by western blot. The ratio of LC3-II/β-Tubulin normalized to control was determined by 




  Fig. 8 Everolimus treatment induces autophagy, which mediates insensitivity. (a) MCF-7, MCF-
7:5C and MCF-7:2A cells were treated with vehicle (a-c), 50µM chloroquine (CQ) (d-f), 20 nM 
everolimus (EVE) (g-i) or both EVE and CQ (j-l) for 48 hours and imaged using electron microscopy. 
Arrows indicate double membrane bound autophagosomes and arrow heads indicate pleomorphic 
mitochondria and dilated endoplasmic reticulum, which could also be seen in untreated MCF-7:5C cells. 
Images a-c are shown at 2000 X magnification while d-f, g-i and j-l are shown at 5000X, 8000X and 
6000X respectively. M, mitochondria; N, nucleus; ER, endoplasmic reticulum. (b) Autophagosomes in a 
minimum of 10 random cells were recorded using de-identified samples. Values are average 
autophagosomes per cell and represent three trials from two separate experiments. (c) Cells were 
seeded in 24-well plates and treated with vehicle, 20 nM everolimus (EVE), 50µM chloroquine or both 
for 7 days. The percentage of viable cells is shown as compared to vehicle treated cells. Bar graphs 
represent the data from three independent experiments in duplicate and values are mean ± SD. * p< 












This study was conducted to provide mechanistic insights into the anti-
proliferative effects of everolimus in AI-resistant MCF-7:5C and MCF-7:2A breast 
cancer cells, and AI-sensitive MCF-7 cells. We found that everolimus was equally 
effective against all three breast cancer cell lines. The anti-proliferative mechanisms 
included downregulation of ER expression and transcriptional activity, possibly through 
the suppression of HSP90. We also demonstrated that everolimus enhanced 4OHT 
sensitivity in all three cell lines. Everolimus treatment significantly induced autophagy, 
which was associated with downregulation of HSP70 and HSP27 expression. 
Additionally, we confirmed that everolimus inhibits the activation of the PI3K/Akt/mTOR 
pathway, resulting in the downregulation of cyclin D1 and p21 expression, which 
induced G1 arrest.  
MCF-7 cells and their derivatives are more resistant to everolimus as compared 
to other luminal A breast cancer cell lines.235,236 Our study is consistent with this 
observation, as total inhibition of the MCF-7, MCF-7:5C and MCF-7:2A cells did not 
exceed 60%, making them suitable to model a patient population that is not highly 
sensitive to everolimus. Additionally, our IC50 values were consistent with the frequent 
use of 20 nM everolimus when studying MCF-7 cell lines.153,237,238 The enhanced 
insensitivity of the MCF-7:5C cells may be due to increased expression of c-myc, which 
is thought to confer some resistance in ER+ breast cancer. 108,239 The slightly enhanced 
sensitivity of the MCF-7:2A cells to everolimus may be related to comparatively lower 
levels of PTEN.108 It should be noted that the MCF-7 and MCF-7:2A cells are 
progesterone receptor-positive (PR+), while the MCF-7:5C cells are PR-negative (PR-) 
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and they overexpresses interferon stimulated genes 59. These differences do not seem 
to mediate any variances in everolimus sensitivity, suggesting that the MCF-7 
background of these cell lines is the most prominent determinant of response.  
Elevated ER expression and signaling has been observed in both endocrine 
resistance cells and endocrine resistant tumors.29,30,240,241 The ability of everolimus to 
reduce ER transcriptional activity and phospho-ER (p-ER) expression in MCF-7/LTED 
cells has been previously reported but was not assessed in wild type MCF-7 cells.220 In 
our study, we found that the inhibition of ER transcriptional activity was due to profound 
downregulation of total ER expression in all cell models. MCF-7:5C and MCF-7:2A cells 
are selected clones maintained in estrogen-free media that have retained ER 
transcriptional activity by upregulation of ER expression and ligand-independent ER 
signaling. In contrast, the MCF-7/LTED cells are a mixed population of cells that have 
developed hypersensitivity to estrogen.242 Additionally, the studies by Martin and 
colleagues were conducted after acute insulin deprivation, which probably contributed to 
the enhanced sensitivity to everolimus and to the impact on both p-ER and p-Akt 
expression in their study. The clinical efficacy of everolimus as a solo agent was thought 
to be limited by a compensatory increase in Akt phosphorylation through mTORC2.153 
We did not observe this reflexive increase in Akt phosphorylation in our cells lines. Our 
results suggest that everolimus as a single agent has the ability to function in a manner 
similar to combination therapy by inhibiting both growth factor and ER signaling 
simultaneously in some systems. Downregulation of total ER expression by everolimus 
has not, to our knowledge, been previously reported. 
168 
 
The downregulation of ER expression was likely due to reduced expression of HSP90, a 
well-known ER chaperone. HSP expression in general is controlled by the 
PI3K/Akt/mTOR pathway through phosphorylation of the transcription factor HSF1 and 
is consistent with the loss of HSP90, HSP27 and HSP70 expression observed in this 
study. 243 Everolimus induced loss of HSP90 mRNA expression has been observed in 
other cancers 222 and a loss of HSP90 expression has been linked to autophagic cell 
death.244  Two HSP90 inhibitors, NVP-AUY922 and STA-9090, are currently in clinical 
trials for the treatment of breast cancer. 245,246 HSP90 inhibitor therapy has been limited 
by reflexive increase in HSP signaling, especially enhanced HSP27 expression.247,248 
Here, we report that everolimus inhibits HSP27 in our cell lines, and so may potentiate 
HSP90 inhibitor treatment. These results suggest that everolimus may be combined 
with HSP90 inhibitors or drugs that target HSP90 clients for the treatment of AI-resistant 
breast cancer. 
AI-resistant tumors are known to retain dependence on ER signaling for growth 
and survival. Given that everolimus reduces ER expression, our observation that it also 
enhances 4OHT sensitivity during long-term co-treatment is very interesting and 
warrants further investigation. It should be noted, however, that everolimus has 
previously been shown to inhibit ER phosphorylation on serine 167 despite documented 
synergy between everolimus and tamoxifen in AI-resistant models and patients. 
153,215,220 It is likely that these two drugs exhibit synergy by targeting ER signaling 
through separate but complementary mechanisms. Our results indicate that everolimus 
reduces ER expression through inhibition of ER mRNA transcription, while tamoxifen 
targets the ER protein. Combining everolimus and tamoxifen ensures that ER signaling 
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is inhibited continuously over time in all cells within a heterogeneous breast tumor. The 
improved efficacy of everolimus in combination with 4OHT in our study is consistent 
with results from the TAMRAD clinical trial.215 The data from our study suggest that 
everolimus could benefit AI-resistant patients with ligand-independent ER activity by 
targeting ER expression and signaling. 
We have demonstrated that everolimus dramatically induces autophagy, and is 
associated with significant downregulation of HSP90, HSP70 and HSP27.  Loss of 
HSP70 and HSP27 is associated with starvation-induced autophagy and rapamycin 
treatment, both of which target the PI3K/Akt/mTOR pathway.229,233 Autophagy is a 
mechanism of drug insensitivity in cancer because it allows tumors to recycle cellular 
components and survive treatment. 224,225 Inhibition of autophagy significantly improved 
the anti-proliferative effects of everolimus in MCF-7, MCF-7:5C and MCF-7:2A cells. 
This is consistent with a previous study reporting enhanced inhibition of MCF-7 cell 
proliferation when combining chloroquine and everolimus.249 Everolimus and other 
PI3K/Akt/mTOR inhibitors are known to induce autophagy in both solid and blood 
tumors 222,223; however, to our knowledge, this phenomenon has not been reported in 
breast cancer cells. We conclude that the induction of autophagy is likely a mechanism 
of everolimus insensitivity in MCF-7 235,236, MCF-7:5C and MCF-7:2A cells.  
Although everolimus treatment induced PARP cleavage in all three cell lines, we 
did not observe apoptotic cell death normally associated with PARP cleavage. PARP 
cleavage is thought to mediate autophagy rather than apoptosis in response to certain 
stimuli.250 Since HSP70 is known to stabilize PARP 251, loss of HSP70-mediated stability 
offers an explanation for the everolimus induced PARP cleavage seen in this study. 
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While there have been reports of autophagic and apoptotic cell death in leukemia 222 
and nasopharyngeal carcinoma cells 252, everolimus is not known to induce cell death in 
breast cancer cells on its own. 222,252 To our knowledge, everolimus induced cell death 
in breast cancer has only been observed in aromatase expressing MCF-7/Aro cells 
when combined with letrozole. 212 We have shown that induction of autophagy limits the 
anti-proliferative response of everolimus treatment, hence a combination of everolimus 
with the autophagy inhibitors chloroquine or hydroxychloroquine, which are currently in 
clinical trials as part of combination therapy 253, may be beneficial in the treatment of AI-
resistant breast cancer. 
CONCLUSION 
Overall, this study demonstrated that everolimus inhibits the proliferation of AI-
resistant breast cancer cells through down regulation of ER expression and also that 
induction of autophagy is a method of everolimus insensitivity. We found that 
everolimus had similar effect on the proliferation of both our AI-sensitive (MCF-7) and 
AI-resistant (MCF-7:5C and MCF-7:2A) models, suggesting that the MCF-7 background 
of these cell lines overrides any other differences that might impact everolimus 
sensitivity. The inhibition of proliferation was seen regardless of PR status, PTEN 
expression, type 1interferon signaling, and 4OHT sensitivity, supporting a conclusion 
that everolimus holds promise as part of combination therapy for a wide variety of AI-





AI  Aromatase inhibitor 
CQ  Chloroquine 
EGF  Epidermal growth factor 
ER  Estrogen receptor 
EVE  Everolimus;  
FUL  Fulvestrant  
HER2  human epidermal growth factor receptor 2  
HIF-1 α hypoxia inducible factor 1 alpha subunit  
HSP27 Heat shock protein 27 
HSP70 Heat shock protein 70 
HSP90 Heat shock protein 90 
IC50  Drug concentration that provides 50% maximal growth inhibition 
LC3B   Microtubule associated light chain 3  
mTOR  Mammalian target of rapamycin 
PARP  Poly ADP ribose polymerase 
PI3K  Phosphoinositide 3-kinase 
PR  Progesterone receptor 
PTEN  Phosphatase and tensin homolog 
P21  Cyclin dependent kinas inhibitor 1 
p70S6K p70 S6 ribosomal protein kinase 
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